Asbestosis - dismech

🏷

Classifications

Harrison's Part

Occupational Disease

?

Discussions and Knowledge Gaps

2

Do pirfenidone or other antifibrotic drugs produce a clinically meaningful benefit in progressive asbestosis?

KNOWLEDGE GAP OPEN gap_asbestosis_antifibrotic_efficacy

Attached to

pathophysiology#Excessive extracellular matrix deposition treatments#Pirfenidone

Available asbestosis-specific studies are small and uncontrolled or real-world before/after analyses; estimates are imprecise, and no adequately powered randomized disease-specific efficacy trial has established benefit.

Show evidence (1 reference)

PMID:41438854 SUPPORT Human Clinical

"Findings based on asbestosis patients treated between 2004 and 2024 reveal a modest reduction in the rate of FVC decline (mean (95% CI) difference 7.0 (-5.8-19.7) mL·month-1, p=0.22) and D LCO decline (0.11% (-0.19-0.41%), p=0.30) after starting pirfenidone"

The latest asbestosis-specific cohort remains statistically inconclusive.

How faithfully do bolus-instilled and short-duration rodent asbestos models reproduce chronic human fiber retention and decades-long asbestosis?

HUMAN MODEL MISMATCH OPEN mismatch_asbestosis_bolus_and_short_term_models

Attached to

pathophysiology#Biopersistent asbestos fiber deposition pathophysiology#Excessive extracellular matrix deposition

Rodent models reproduce deposition, macrophage recruitment, TGF-beta signaling, and collagen deposition, but their delivery route, dose, lung anatomy, clearance kinetics, and compressed timescale differ materially from chronic occupational inhalation in humans.

Show evidence (1 reference)

PMID:3004226 SUPPORT Model Organism

"The lesions were induced by intratracheal instillation of 1 mg crocidolite asbestos in mice, which were killed up to 20 weeks thereafter"

The experimental exposure and timescale document the central translational mismatch.

⚙

Pathophysiology

10

Biopersistent asbestos fiber deposition

Inhaled asbestos fibers with a high length-to-width (aspect) ratio deposit at alveolar duct bifurcations and in the distal airspaces. Amphibole fibers (crocidolite, amosite) are cleared poorly and are retained for decades (biopersistence); over time host cells encase retained fibers in an iron-protein coat, forming ferruginous asbestos bodies. This retained, biopersistent fiber burden is the injurious insult that initiates the disease.

alveolar macrophage CL:0000583 alveolar type I epithelial cell CL:0002062 alveolar type II epithelial cell CL:0002063

lung UBERON:0002048

Downstream

Frustrated phagocytosis of asbestos fibers

Show evidence (1 reference)

PMID:37569765 SUPPORT Other

"An inability to clear asbestos from the lower respiratory tract initiates a host process of iron biomineralization (i.e., asbestos body formation)."

Supports biopersistence of retained fibers and iron-coated asbestos body formation as the hallmark of failed clearance.

Frustrated phagocytosis of asbestos fibers

Alveolar macrophages attempt to engulf the deposited fibers, but long fibers physically cannot be fully internalized. This "frustrated phagocytosis" leaves macrophages persistently activated and unable to clear the fiber, with leakage of lysosomal contents at the incomplete phagosome.

alveolar macrophage CL:0000583

frustrated phagocytosis of asbestos fibers GO:0006909 ⚠ ABNORMAL

Experimental models

Asbestos-exposed macrophage culture PRIMARY CELL CULTURE Resolves fiber-length-dependent uptake failure and macrophage signaling.

Downstream

Iron-catalyzed reactive oxygen species generation

Show evidence (1 reference)

PMID:37894824 SUPPORT In Vitro

"the response to LFA was elicited by a multifactorial ignition system involving the macrophage receptor with collagenous structure (SR-A6 or MARCO), reactive oxygen species (ROS) cascade, and TLR4"

In macrophage cultures, non-internalizable long amosite fibers trigger a distinct MARCO/ROS/TLR4 response, the signature of frustrated phagocytosis of long fibers.

Iron-catalyzed reactive oxygen species generation

Iron adsorbed onto the fiber surface (and within asbestos bodies) plus macrophage superoxide produced at the phagosome membrane drive Fenton-type generation of hydroxyl radicals. The resulting reactive oxygen species directly injure alveolar epithelial DNA and membranes and activate redox-sensitive signaling.

alveolar macrophage CL:0000583 alveolar type I epithelial cell CL:0002062

reactive oxygen species generation GO:0072593 ↑ INCREASED response to oxidative stress GO:0006979 ↑ INCREASED

Downstream

NLRP3 inflammasome activation

Show evidence (1 reference)

PMID:37569765 SUPPORT Other

"Host cells attempt to mobilize the metal sequestered by the fiber surface by producing superoxide at the phagosome membrane."

Supports macrophage superoxide (reactive oxygen species) generation at the fiber-laden phagosome as the proximal oxidative-injury mechanism.

NLRP3 inflammasome activation

Asbestos fibers activate the NLRP3 inflammasome in alveolar macrophages, driving caspase-1-dependent maturation and release of IL-1beta and IL-18. Fiber-generated reactive oxygen species and lysosomal destabilization are upstream triggers of this sterile inflammasome response.

alveolar macrophage CL:0000583

NLRP3 inflammasome complex assembly GO:0044546 ↑ INCREASED

Experimental models

Asbestos-exposed macrophage culture PRIMARY CELL CULTURE Measures inflammasome-dependent cytokine release after fiber exposure.

Downstream

Chronic sterile alveolitis

Show evidence (1 reference)

PMID:21800904 SUPPORT In Vitro

"the NLRP3 inflammasome was essential for long, needle-like CNT and asbestos-induced IL-1β secretion"

In human primary macrophages, asbestos-induced IL-1beta secretion requires the NLRP3 inflammasome.

Chronic sterile alveolitis

IL-1beta and IL-18 amplify recruitment and activation of macrophages and neutrophils in the distal lung, initiating a sterile inflammatory response that promotes the fibrotic program. Established histologic asbestosis may show little active inflammation, so this node represents the mediator phase rather than persistent inflammatory infiltrates in every case.

alveolar macrophage CL:0000583 neutrophil CL:0000775

inflammatory response GO:0006954 ↑ INCREASED

Downstream

Pro-fibrotic mediator release

Show evidence (1 reference)

PMID:37569765 SUPPORT Other

"activates kinases and transcription factors, which are associated with the release of mediators coordinating both inflammatory and fibrotic responses"

Links the fiber-triggered cellular response to mediators that coordinate the inflammatory alveolitis and its transition to fibrosis.

Pro-fibrotic mediator release

Activated macrophages and injured epithelial cells release pro-fibrotic growth factors - chiefly TGF-beta, plus PDGF, IGF-1, and fibronectin - that shift the chronic inflammatory response toward tissue remodeling. This mediator surge is the bridge from inflammation to mesenchymal activation. TGF-beta is the mediator with direct experimental support here: forced pulmonary TGF-beta1 expression is by itself sufficient to produce fibroproliferative lung disease. The accompanying PDGF, IGF-1, and fibronectin claims are drawn from the wider fibrosis literature and are not separately evidenced in this entry.

alveolar macrophage CL:0000583

transforming growth factor beta production GO:0071604 ↑ INCREASED

Downstream

Myofibroblast differentiation

Show evidence (3 references)

PMID:12444030 SUPPORT Model Organism

"both strains of mice were treated intratracheally with an adenovirus vector (AdV), which transduces expression of active transforming growth factor (TGF)-beta(1) in the lungs, producing fibroproliferative lung disease"

Pulmonary TGF-beta1 expression alone produces fibroproliferative lung disease in mice, supporting TGF-beta release as the mediator bridging inflammation to the fibrotic response.

PMID:37569765 SUPPORT Other

"activates kinases and transcription factors, which are associated with the release of mediators coordinating both inflammatory and fibrotic responses"

Review places mediator release downstream of the fiber-triggered cell response and upstream of the coordinated inflammatory and fibrotic programs. Evidence source OTHER (review).

PMID:23463177 SUPPORT Model Organism

"Exposure to asbestos caused rat AM to exhibit high production of transforming growth factor-beta (TGF-β) with prolonged survival in the absence of other cells"

Asbestos-exposed rat alveolar macrophages directly produced high TGF-beta.

Myofibroblast differentiation

TGF-beta recruits fibroblasts to the injured interstitium and drives their differentiation into contractile, matrix-secreting alpha-SMA-positive myofibroblasts. This mesenchymal activation is the proximate cellular driver of matrix accumulation.

lung fibroblast CL:0000057 myofibroblast CL:0000186

fibroblast migration GO:0010761 ↑ INCREASED TGF-beta receptor signaling GO:0007179 ↑ INCREASED myofibroblast differentiation GO:0036446 ↑ INCREASED

Downstream

Excessive extracellular matrix deposition

Show evidence (1 reference)

PMID:12444030 SUPPORT Model Organism

"both strains of mice were treated intratracheally with an adenovirus vector (AdV), which transduces expression of active transforming growth factor (TGF)-beta(1) in the lungs, producing fibroproliferative lung disease"

In a mouse model, lung TGF-beta1 expression is sufficient to produce fibroproliferative lung disease, supporting TGF-beta-driven fibroblast-to-myofibroblast activation.

Excessive extracellular matrix deposition

Activated myofibroblasts deposit excess type I collagen and other matrix components in the alveolar walls and interstitium, beginning around respiratory bronchioles and extending into the alveolar interstitium. The accumulated matrix is what makes asbestosis a diffuse fibrosing parenchymal disease; the specific collagen subtype and the bronchiolocentric starting point are drawn from the wider pathology literature rather than from a source curated in this entry.

myofibroblast CL:0000186

collagen fibril organization GO:0030199 ↑ INCREASED extracellular matrix organization GO:0030198 ⚠ ABNORMAL

Downstream

Interstitial fibrosis and architectural distortion

Show evidence (3 references)

PMID:38192052 SUPPORT Human Clinical

"Asbestosis, defined as diffuse pulmonary fibrosis caused by inhalation of asbestos fibers, occurs after heavy exposures to asbestos dust over several decades."

Diffuse pulmonary fibrosis - the accumulated matrix this node deposits - is the defining lesion in a 102-case clinicopathological series.

PMID:32553000 SUPPORT Other

"Deposition in the lung parenchyma results in an inflammatory/progressively fibrotic response, with impaired gas exchange and reduced lung compliance ('asbestosis')"

Review links parenchymal fiber deposition to the progressive fibrotic (matrix-accumulating) response that defines asbestosis. Evidence source OTHER (review).

PMID:3004226 SUPPORT Model Organism

"Increased collagen levels were largely due to stimulation of peribronchial fibroblasts."

A mouse crocidolite-instillation model links fibroblast stimulation to increased pulmonary collagen.

Interstitial fibrosis and architectural distortion

Accumulating matrix thickens the air-blood barrier and produces lower-zone-predominant interstitial fibrosis, progressively obliterating normal alveolar architecture with honeycombing in advanced disease. This is the defining parenchymal lesion of asbestosis.

wound healing GO:0042060 ↕ DYSREGULATED

lung UBERON:0002048

Downstream

Restrictive ventilatory failure

Diffuse interstitial pulmonary fibrosis

Inspiratory crackles

Show evidence (1 reference)

PMID:38192052 SUPPORT Human Clinical

"Asbestosis, defined as diffuse pulmonary fibrosis caused by inhalation of asbestos fibers, occurs after heavy exposures to asbestos dust over several decades."

Confirms diffuse interstitial pulmonary fibrosis as the defining structural lesion of asbestosis.

Restrictive ventilatory failure

Loss of lung compliance and impaired gas exchange from the interstitial fibrosis produce a restrictive ventilatory defect with reduced diffusing capacity and chronic hypoxemia, progressing in advanced disease to pulmonary hypertension, cor pulmonale, and respiratory failure.

lung UBERON:0002048

Downstream

Exertional dyspnea

Restrictive ventilatory defect

Decreased DLCO

Reduced forced vital capacity

Respiratory failure

Show evidence (1 reference)

PMID:32553000 SUPPORT Other

"Deposition in the lung parenchyma results in an inflammatory/progressively fibrotic response, with impaired gas exchange and reduced lung compliance ('asbestosis')"

Confirms the terminal physiologic outcome: impaired gas exchange and reduced lung compliance (restrictive physiology).

✶

Histopathology

1

Diffuse interstitial fibrosis with asbestos (ferruginous) bodies

The diagnostic histologic lesion is diffuse interstitial fibrosis in the appropriate anatomic distribution together with identifiable asbestos (ferruginous) bodies - golden-brown, beaded, iron-protein-coated fibers - or a documented elevated lung fiber burden. Amphibole fibers (especially amosite) predominate in fiber-burden analyses, and pleural plaques commonly coexist as a marker of exposure.

Show evidence (2 references)

PMID:38192052 SUPPORT Human Clinical

"Lung fiber burden analysis was performed in 34 cases, with amosite being the predominant fiber type."

Amphibole (amosite) fibers predominate in the retained lung fiber burden of pathologically confirmed asbestosis cases.

PMID:38192052 SUPPORT Human Clinical

"Pleural plaque was present in 94% of cases."

Pleural plaques frequently coexist with parenchymal asbestosis as a marker of prior asbestos exposure, though they are a separate lesion.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

9

Respiratory 3

Nonproductive cough HP:0031246

Show evidence (1 reference)

ORPHA:2302 SUPPORT Other

"Symptoms may appear many years after exposure and include progressive dyspnea on exertion, dry cough, chest pain, tightness, inspiratory crackles, clubbing of the fingers."

Orphanet lists dry cough among asbestosis symptoms.

Restrictive ventilatory defect HP:0002091

Show evidence (1 reference)

PMID:32553000 SUPPORT Other

"impaired gas exchange and reduced lung compliance ('asbestosis')"

Reduced lung compliance and impaired gas exchange are the physiologic hallmark of the restrictive defect in asbestosis.

Respiratory failure HP:0002878

Severity: SEVERE

Show evidence (1 reference)

PMID:32553000 SUPPORT Other

"causing progressive dyspnoea and respiratory failure for which only palliation is indicated"

Review explicitly identifies respiratory failure as an advanced consequence.

Other 6

Exertional dyspnea HP:0002875

Course: PROGRESSIVE

Show evidence (2 references)

PMID:32553000 SUPPORT Other

"causing progressive dyspnoea and respiratory failure for which only palliation is indicated"

Review identifies progressive dyspnea (advancing to respiratory failure) as the defining clinical consequence of the asbestosis fibrotic response.

ORPHA:2302 SUPPORT Other

"Symptoms may appear many years after exposure and include progressive dyspnea on exertion, dry cough, chest pain, tightness, inspiratory crackles, clubbing of the fingers."

Orphanet explicitly identifies progressive dyspnea on exertion.

Inspiratory crackles HP:0031996

Show evidence (2 references)

PMID:464386 SUPPORT Human Clinical

"bilateral fine crackles, clubbing, dyspnea, radiographic abnormality, decreased forced vital capacity, and decreased single-breath diffusing capacity of the lung for CO"

Bilateral fine crackles were a standardized clinical manifestation in asbestos-exposed workers.

ORPHA:2302 SUPPORT Other

"Symptoms may appear many years after exposure and include progressive dyspnea on exertion, dry cough, chest pain, tightness, inspiratory crackles, clubbing of the fingers."

Orphanet explicitly identifies inspiratory crackles.

Diffuse interstitial pulmonary fibrosis Bilateral basilar pulmonary fibrosis HP:0550005

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:38192052 SUPPORT Human Clinical

"Asbestosis, defined as diffuse pulmonary fibrosis caused by inhalation of asbestos fibers, occurs after heavy exposures to asbestos dust over several decades."

Confirms diffuse pulmonary fibrosis as the defining parenchymal lesion of asbestosis.

Digital clubbing Clubbing of fingers HP:0100759

Show evidence (1 reference)

PMID:9230732 SUPPORT Human Clinical

"Dyspnea, a low FVC, and/or physical examination findings typical of interstitial fibrosis (rales, clubbing, or cyanosis) raised the risk of subsequent death from asbestosis by 2- to 6-fold."

Clubbing was documented as a clinical sign and adverse prognostic marker in a large insulator cohort.

Decreased DLCO HP:0045051

Show evidence (1 reference)

PMID:464386 SUPPORT Human Clinical

"bilateral fine crackles, clubbing, dyspnea, radiographic abnormality, decreased forced vital capacity, and decreased single-breath diffusing capacity of the lung for CO"

Reduced diffusing capacity was measured as a manifestation in asbestos-exposed workers.

Reduced forced vital capacity HP:0032341

Show evidence (1 reference)

PMID:464386 SUPPORT Human Clinical

"bilateral fine crackles, clubbing, dyspnea, radiographic abnormality, decreased forced vital capacity, and decreased single-breath diffusing capacity of the lung for CO"

Reduced FVC was measured in standardized examinations of asbestos-exposed workers.

🧬

Genetic Associations

2

GSTM1 (Homozygous GSTM1 (glutathione S-transferase mu-1) deletion / null genotype has been proposed as a gene-environment susceptibility modifier for nonmalignant asbestos-related disease, plausibly by reducing detoxification of fiber-generated reactive electrophiles and oxidants. The evidence is conflicting: an early cross-sectional study found increased risk, whereas a later, larger nested case-control study found no GSTM1 association.)

Gene: GSTM1 hgnc:4632 relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE

Show evidence (2 references)

PMID:8000297 SUPPORT Human Clinical

"Individuals genetically deficient in GST-mu were significantly more likely to have radiographic evidence of nonmalignant asbestos-related disease than those who were not deficient"

In asbestos-exposed carpenters, homozygous GSTM1 deletion was associated with radiographic nonmalignant asbestos-related disease, but the snippet does not isolate pathologically confirmed asbestosis and later evidence was null; it therefore only partially supports an asbestosis modifier.

PMID:17563610 REFUTE Human Clinical

"but not with GSTM1-null genotype (OR=1.01, CI 0.71-1.43)"

A larger nested case-control study found no association between the GSTM1-null genotype and asbestosis, conflicting with the earlier report.

GSTT1 (In a nested case-control study, the GSTT1 (glutathione S-transferase theta-1) null genotype was associated with a reduced risk of asbestosis (a protective effect), independent of cumulative exposure.)

Gene: GSTT1 hgnc:4641 relationship_type: PROTECTIVE variant_origin: GERMLINE

Show evidence (1 reference)

PMID:17563610 SUPPORT Human Clinical

"GSTT1 gene deletion might have a protective effect on the development of asbestosis"

The study concluded that the GSTT1-null genotype may protect against the development of asbestosis.

💊

Medical Actions

7

Smoking cessation

Action: smoking cessation Ontology label: Smoking Cessation Intervention NCIT:C15372

Smoking cessation is strongly advised because tobacco smoke and asbestos act multiplicatively to increase lung cancer risk.

Show evidence (1 reference)

PMID:32553000 SUPPORT Other

"Bronchogenic carcinoma risk from asbestos exposure is dose-dependent and multiplies the risk attributable to tobacco smoking."

The multiplicative interaction between asbestos and tobacco on lung cancer risk is the rationale for prioritizing smoking cessation in asbestos-exposed patients.

Supplemental oxygen therapy

Action: supplemental oxygen therapy Ontology label: Oxygen Therapy NCIT:C94624

Long-term oxygen for chronic hypoxemia in advanced disease.

Show evidence (1 reference)

PMID:32553000 SUPPORT Other

"causing progressive dyspnoea and respiratory failure for which only palliation is indicated"

Supports palliative/supportive management (of which supplemental oxygen is a component) as the available approach for progressive dyspnoea and respiratory failure. Marked PARTIAL: the review does not name oxygen therapy specifically. Evidence source OTHER (review).

Pulmonary rehabilitation

Action: pulmonary rehabilitation Ontology label: Pulmonary Rehabilitation NCIT:C157966

Structured exercise and education to improve exertional capacity and quality of life.

Show evidence (1 reference)

PMID:32053838 SUPPORT Human Clinical

"specific exercise therapy and sports are able to mobilize physical reserves of performance and induce an increasing quality of life as well as a higher resilience in activities of daily living"

An 8-year follow-up of outpatient pulmonary rehabilitation in asbestosis patients shows exercise therapy improves quality of life and daily-living resilience despite the irreversible restrictive disease.

Lung transplantation

Action: organ transplantation Ontology label: Organ Transplantation NCIT:C15289

Considered in selected patients with end-stage fibrosis.

Removal from ongoing asbestos exposure

Ending further asbestos exposure is a cardinal management step. Because asbestosis risk is dose-dependent on cumulative fiber burden, halting additional exposure limits further accrual of injurious fiber load. It does not reverse established fibrosis (retained fibers are biopersistent), so it is preventive of progression rather than curative.

Show evidence (1 reference)

PMID:38577971 SUPPORT Human Clinical

"We found increasing incidence rate ratios (IRR) of asbestosis with increasing cumulative asbestos exposure with a fully adjusted IRR per 1 f/ml-years of 1.18"

The dose-dependent cumulative-exposure relationship is the rationale for removal from further asbestos exposure to limit additional risk.

Vaccination

Action: vaccination Ontology label: Vaccination NCIT:C15346

Influenza and pneumococcal vaccination are recommended supportive measures to reduce respiratory infections that can precipitate acute decompensation in chronic fibrotic lung disease.

Pirfenidone

Action: Pharmacotherapy NCIT:C15986

Agent: pirfenidone CHEBI:32016

Investigational antifibrotic therapy for progressive asbestosis. A 10-patient prospective safety study found acceptable tolerability but no significant change in hospital PFTs, and a later real-world analysis found only modest, statistically non-significant changes in FVC and DLCO decline. It is not established disease-modifying standard therapy.

Show evidence (2 references)

PMID:35643466 SUPPORT Human Clinical

"No significant changes in hospital pulmonary function (forced vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLCO), 6 min walking test or patient-reported outcomes measures before and after start of pirfenidone were found."

Small prospective study supports feasibility and safety but not established efficacy.

PMID:41438854 SUPPORT Human Clinical

"Findings based on asbestosis patients treated between 2004 and 2024 reveal a modest reduction in the rate of FVC decline (mean (95% CI) difference 7.0 (-5.8-19.7) mL·month-1, p=0.22) and D LCO decline (0.11% (-0.19-0.41%), p=0.30) after starting pirfenidone"

Real-world before/after estimates are compatible with modest benefit but are imprecise and non-significant.

🌍

Environmental Factors

1

Occupational asbestos inhalation

Hazard type: CHEMICAL

Route: INHALATION

Duration: CHRONIC

IARC group: GROUP 1

GHS hazard class: CARCINOGENICITY STOT REPEATED EXPOSURE

Exposome domain: SPECIFIC EXTERNAL

Inhalation of airborne asbestos fibers during mining, milling, shipbuilding, insulation, construction, brake-lining, and textile work is the dominant exposure route. Both amphibole fibers (crocidolite, amosite) and, to a lesser fibrogenic degree, serpentine chrysotile can cause asbestosis; long, thin, biopersistent amphibole fibers are the most fibrogenic. Risk is dose-dependent (cumulative fiber burden) and paraoccupational/household and environmental exposures also occur.

Show evidence (4 references)

PMID:29772681 SUPPORT Other

"The first identified disease was asbestosis, a type of incurable pneumoconiosis caused by asbestos dust and fibres."

Establishes asbestosis as an incurable pneumoconiosis caused by inhaled asbestos dust and fibers.

PMID:36630203 SUPPORT Other

"asbestos-related pulmonary complications include asbestosis, pleural plaques, diffuse pleural thickening, benign asbestos-related pleural effusions and malignant pleural mesothelioma"

Places asbestosis within, and distinct from, the broader spectrum of asbestos-related pulmonary and pleural diseases, supporting the scope boundary stated in the description.

PMID:38577971 SUPPORT Human Clinical

"We found increasing incidence rate ratios (IRR) of asbestosis with increasing cumulative asbestos exposure with a fully adjusted IRR per 1 f/ml-years of 1.18"

A large Danish general-working-population cohort demonstrates a dose-dependent exposure-response relationship between cumulative asbestos exposure and incident asbestosis.

+ 1 more reference

Mechanism Target:

TRIGGERS Biopersistent asbestos fiber deposition — Inhalation of airborne fibers is what delivers them to the distal airspaces, so the retained biopersistent fiber burden scales with cumulative occupational exposure.

Show evidence (1 reference)

PMID:38577971 SUPPORT Human Clinical

"We found increasing incidence rate ratios (IRR) of asbestosis with increasing cumulative asbestos exposure with a fully adjusted IRR per 1 f/ml-years of 1.18"

Disease incidence rises with cumulative fiber-years of exposure, the dose-response expected if inhaled exposure is what builds the retained fiber burden that initiates injury.

🔬

Diagnosis

3

Exposure history and high-resolution chest CT correlation

Diagnosis requires a credible asbestos exposure with appropriate latency, compatible bilateral basal/subpleural fibrosis on HRCT, and exclusion of a better explanation. Pleural plaques support prior exposure but are neither necessary nor sufficient for parenchymal asbestosis.

High-resolution chest computed tomography NCIT:C17204

Results: Basal/subpleural interstitial fibrosis; subpleural dots, short subpleural lines, and parenchymal bands favor asbestosis over idiopathic pulmonary fibrosis.

Show evidence (1 reference)

PMID:26901505 SUPPORT Human Clinical

"On multivariate analysis, HRCT features that distinguished asbestosis from IPF were subpleural lines at a distance of less than 5 mm from the inner chest wall, subpleural dots and parenchymal bands."

Comparative imaging study identifies HRCT features useful in the principal differential.

Pulmonary function testing

Spirometry, lung volumes, and DLCO establish physiologic impairment and provide longitudinal severity/progression measures; they support but do not establish asbestos causation.

Pulmonary Function Test NCIT:C38081

Results: Restriction, reduced forced vital capacity, and reduced diffusing capacity.

Show evidence (1 reference)

PMID:464386 SUPPORT Human Clinical

"bilateral fine crackles, clubbing, dyspnea, radiographic abnormality, decreased forced vital capacity, and decreased single-breath diffusing capacity of the lung for CO"

Standardized worker examinations document the characteristic functional abnormalities.

Lung biopsy and quantitative fiber burden when noninvasive evaluation is indeterminate

Tissue is not routinely required, but in disputed or atypical cases the combination of appropriate interstitial fibrosis and excess asbestos bodies or quantitative fiber burden can establish pathologic attribution.

Lung Biopsy NCIT:C51748

Results: Appropriate fibrosis plus evidence of excess pulmonary asbestos burden.

Show evidence (1 reference)

PMID:20196674 SUPPORT Other

"Two or more asbestos bodies per square centimeter of a 5- mu m-thick lung section, in combination with interstitial fibrosis of the appropriate pattern, are indicative of asbestosis."

Consensus pathology criteria define a tissue asbestos-body threshold with compatible fibrosis.

📈

Progression

3

Latent interval

Age: Adult onset, usually more than 20 years after first exposure Duration: Usually more than 20 years from first exposure to symptoms

The latency is exposure-to-clinical-disease time, not an incubation period.

Show evidence (1 reference)

PMID:20196674 SUPPORT Other

"Clinically, the disease usually progresses slowly, with a typical latent period of more than 20 years from first exposure to onset of symptoms."

Consensus pathology review supports the characteristic long latency and slow tempo.

Established fibrotic disease

Duration: Chronic and variably progressive

More than 20% of one follow-up cohort met its progressive-disease threshold; this cohort-specific result is not treated as a universal frequency.

Show evidence (1 reference)

PMID:31226624 SUPPORT Human Clinical

"More than 20% of our cohort have a progressive disease with an annual loss of FVC > -100 ml."

Longitudinal pulmonary-function data identify a progressive subgroup.

Long-term outcome

Duration: Median estimated survival 124 months in one 100-patient referral cohort

Survival estimates are cohort- and severity-dependent and must not be read as a universal life expectancy. Lower DLCO, older age, higher composite physiologic index, and higher GAP stage predicted worse survival.

Show evidence (2 references)

PMID:33637623 SUPPORT Human Clinical

"The median estimated survival of the patients was 124 months, that is, 171 months in GAP stage I, 50 months in stage II and 21 months in stage III (p<0.001)."

Provides severity-stratified survival estimates from a defined clinical cohort.

PMID:41612278 SUPPORT Human Clinical

"Mortality in asbestosis was associated with lung cancer, pulmonary hypertension (PH), and atrial fibrillation, whereas in IPF, it was linked to FVC < 80% and PH."

A prospective cohort identifies complication-specific mortality associations through 2022 follow-up.

📊

Prevalence

1

Global

Annual Incidence Unknown

The Global Burden of Disease 2019 analysis estimated 36,339 incident cases worldwide in 2019. A denominator-based global incidence rate was not quoted in the abstract, so no normalized rate is asserted here. Burden is strongly heterogeneous by country and reflects historical exposure and surveillance.

Show evidence (1 reference)

PMID:37591378 SUPPORT Computational

"Globally, 36,339 incident cases of asbestosis, led to 3572 deaths and 71,225 disability adjusted life years (DALYs) in 2019."

GBD 2019 modeling provides disease-specific global annual burden estimates.

⚖️

Clinical Burden

High

Established disease is irreversible and may cause progressive exertional limitation, oxygen dependence, pulmonary hypertension, respiratory failure, and excess mortality, although individual tempo varies substantially.

Show evidence (1 reference)

PMID:33637623 SUPPORT Human Clinical

"CPI, DLCO% predicted, age at baseline and GAP stage were significant predictors of mortality (all p values under 0.001)."

Physiologic severity and age materially stratify mortality risk.

🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Asbestosis:

Idiopathic pulmonary fibrosis MONDO:0800504

Overlapping Features Both disorders can show basal, subpleural fibrosis with a UIP-like pattern.

Distinguishing Features

A credible high cumulative asbestos exposure, pleural fibrosis/plaques, asbestos bodies or elevated lung fiber burden, and subpleural dots/lines or parenchymal bands favor asbestosis. Fibroblastic foci and active inflammation are more characteristic of IPF.

Show evidence (1 reference)

PMID:20196674 SUPPORT Other

"The pulmonary fibrosis of asbestosis is interstitial and has a basal subpleural distribution, similar to that seen in idiopathic pulmonary fibrosis, which is the principal differential diagnosis."

Consensus review explicitly identifies IPF as the principal differential.

📊

Related Datasets

1

Gene expression in asbestos exposed lung cells geo:GSE6013

Asbestos has been shown to cause chromosomal damage and DNA aberrations. The fiber is associated with many different lung diseases such as asbestosis, malignant mesothelioma, and lung cancer, but the disease-related processes are still largely unknown. Our aim was to identify specific gene expression profiles by using Affymetrix arrays, in human cell lines A549, Beas-2B, and MeT5A exposed to asbestos in a time-dependent manner.

human MICROARRAY n=27

PMID:17331233

Identified by GEO DataSets index search for Asbestosis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.

🔬

Clinical Trials

1

NCT05133453 NOT_APPLICABLE UNKNOWN

Registry-listed study of pirfenidone efficacy and prognosis in clinically and radiologically defined asbestosis. The cached registry record reports unknown status and no posted results; no efficacy inference is made.

Target Phenotypes: Reduced forced vital capacity HP:0032341

Show evidence (1 reference)

clinicaltrials:NCT05133453 SUPPORT Human Clinical

"This study aims at determining the the efficiency and prognosis of using pirfenidone drug among asbestosis patients."

Trial registry summary establishes the asbestosis-specific pirfenidone study objective only.

🧫

Experimental Models

1

Asbestos-exposed macrophage culture PRIMARY_CELL_CULTURE

Macrophage cultures expose cells to defined fiber lengths to resolve phagocytosis, ROS, TLR4/MARCO signaling, inflammasome activation, cytokine release, and death programs. The model lacks epithelial-mesenchymal and clearance dynamics of the intact human lung.

Cell source

Murine macrophages

Culture

In-vitro fiber exposure

Publication

PMID:37894824

Pathograph links

Frustrated phagocytosis of asbestos fibers Resolves fiber-length-dependent uptake failure and macrophage signaling.

Show evidence (1 reference)

PMID:37894824 SUPPORT In Vitro

"macrophage responses to non-internalizable LFA were associated with tumor necrosis factor alpha (TNF-α) release, caspase-3 and -7 activation, and apoptosis"

Long fibers were non-internalizable and elicited macrophage signaling, supporting uptake failure without explicitly naming frustrated phagocytosis.

NLRP3 inflammasome activation Measures inflammasome-dependent cytokine release after fiber exposure.

Show evidence (1 reference)

PMID:37894824 SUPPORT In Vitro

"SFA internalization resulted in pyroptotic-related immunogenic cell death (ICD) characterized by the release of the pro-inflammatory damage signal (DAMP) IL-1α after inflammasome activation and gasdermin D (GSDMD)-pore formation."

Short-fiber internalization activated an inflammasome and pyroptotic signaling, but the abstract does not identify NLRP3 specifically.

Show evidence (1 reference)

PMID:37894824 SUPPORT In Vitro

"the response to LFA was elicited by a multifactorial ignition system involving the macrophage receptor with collagenous structure (SR-A6 or MARCO), reactive oxygen species (ROS) cascade, and TLR4"

Defines the long-fiber macrophage signaling phenotype reproduced in vitro.

🐁

Animal Models

2

Rat (Rattus norvegicus) Induced inhalation model

Brief aerosolized chrysotile exposure produces deposition at first alveolar duct bifurcations, macrophage accumulation, TGF-beta localization, and early fibronectin/alpha-smooth-muscle-actin-positive fibrogenic lesions. It models early spatial events but compresses decades of human latency.

Species

Rat (Rattus norvegicus)

Show evidence (1 reference)

PMID:8027525 SUPPORT Model Organism

"These sites, the first alveolar duct bifurcations, are where the fibers are initially deposited and where macrophages first accumulate."

Defines the spatially resolved rat inhalation model and its earliest cellular events.

Mouse (Mus musculus) Induced intratracheal instillation model

Intratracheal crocidolite causes epithelial injury, sustained alveolar macrophage accumulation, fibroblast stimulation, and increased collagen over a 20-week course. Bolus instillation does not reproduce human aerosol dose, fiber clearance, or latency.

Species

Mouse (Mus musculus)

Show evidence (1 reference)

PMID:3004226 SUPPORT Model Organism

"The lesions were induced by intratracheal instillation of 1 mg crocidolite asbestos in mice, which were killed up to 20 weeks thereafter"

Establishes the induced mouse model, exposure method, dose, and study duration.

{ }

Source YAML

click to show

name: Asbestosis
creation_date: "2026-07-16T00:00:00Z"
category: Respiratory Disease
parents:
- Respiratory Disease
- Lung Disease
- Pneumoconiosis
disease_term:
  preferred_term: asbestosis
  term:
    id: MONDO:0016466
    label: asbestosis
description: >-
  Asbestosis is a chronic, diffuse interstitial pulmonary fibrosis caused by the
  inhalation and retention of asbestos mineral fibers. It is a dose-dependent
  pneumoconiosis with a long latency (typically 15-40 years from first exposure)
  in which biopersistent fibers deposited in the distal airways and alveoli
  provoke sustained oxidative injury, chronic inflammation, and progressive,
  irreversible lower-zone-predominant fibrosis. Asbestosis denotes the
  parenchymal fibrosis specifically and is distinct from the other
  asbestos-related diseases (benign pleural plaques and effusions, diffuse
  pleural thickening, lung carcinoma, and malignant mesothelioma), which arise by
  overlapping but separable mechanisms.
synonyms:
- asbestos pneumoconiosis
- asbestos dust pneumoconiosis
- pulmonary asbestosis
prevalence:
- population: Global
  measure_type: ANNUAL_INCIDENCE
  prevalence_class: UNKNOWN
  notes: >-
    The Global Burden of Disease 2019 analysis estimated 36,339 incident cases
    worldwide in 2019. A denominator-based global incidence rate was not quoted
    in the abstract, so no normalized rate is asserted here. Burden is strongly
    heterogeneous by country and reflects historical exposure and surveillance.
  evidence:
  - reference: PMID:37591378
    reference_title: "Global, regional, and national burden of asbestosis from 1990 to 2019 and the implications for prevention and control."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "Globally, 36,339 incident cases of asbestosis, led to 3572 deaths and 71,225 disability adjusted life years (DALYs) in 2019."
    explanation: GBD 2019 modeling provides disease-specific global annual burden estimates.
progression:
- phase: Latent interval
  age_range: Adult onset, usually more than 20 years after first exposure
  duration: Usually more than 20 years from first exposure to symptoms
  notes: The latency is exposure-to-clinical-disease time, not an incubation period.
  evidence:
  - reference: PMID:20196674
    reference_title: "Pathology of asbestosis- An update of the diagnostic criteria: Report of the asbestosis committee of the college of american pathologists and pulmonary pathology society."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Clinically, the disease usually progresses slowly, with a typical latent period of more than 20 years from first exposure to onset of symptoms."
    explanation: Consensus pathology review supports the characteristic long latency and slow tempo.
- phase: Established fibrotic disease
  duration: Chronic and variably progressive
  notes: >-
    More than 20% of one follow-up cohort met its progressive-disease threshold;
    this cohort-specific result is not treated as a universal frequency.
  evidence:
  - reference: PMID:31226624
    reference_title: "The natural course of lung function decline in asbestos exposed subjects with pleural plaques and asbestosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "More than 20% of our cohort have a progressive disease with an annual loss of FVC > -100 ml."
    explanation: Longitudinal pulmonary-function data identify a progressive subgroup.
- phase: Long-term outcome
  duration: Median estimated survival 124 months in one 100-patient referral cohort
  notes: >-
    Survival estimates are cohort- and severity-dependent and must not be read as
    a universal life expectancy. Lower DLCO, older age, higher composite
    physiologic index, and higher GAP stage predicted worse survival.
  evidence:
  - reference: PMID:33637623
    reference_title: "Survival of patients with asbestosis can be assessed by risk-predicting models."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The median estimated survival of the patients was 124 months, that is, 171 months in GAP stage I, 50 months in stage II and 21 months in stage III (p<0.001)."
    explanation: Provides severity-stratified survival estimates from a defined clinical cohort.
  - reference: PMID:41612278
    reference_title: "Distinct comorbidity profiles and outcomes in asbestosis versus idiopathic pulmonary fibrosis: a 6-year prospective cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mortality in asbestosis was associated with lung cancer, pulmonary hypertension (PH), and atrial fibrillation, whereas in IPF, it was linked to FVC < 80% and PH."
    explanation: A prospective cohort identifies complication-specific mortality associations through 2022 follow-up.
clinical_burden:
  burden_level: HIGH
  rationale: >-
    Established disease is irreversible and may cause progressive exertional
    limitation, oxygen dependence, pulmonary hypertension, respiratory failure,
    and excess mortality, although individual tempo varies substantially.
  evidence:
  - reference: PMID:33637623
    reference_title: "Survival of patients with asbestosis can be assessed by risk-predicting models."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CPI, DLCO% predicted, age at baseline and GAP stage were significant predictors of mortality (all p values under 0.001)."
    explanation: Physiologic severity and age materially stratify mortality risk.
classifications:
  harrisons_chapter:
  - classification_value: RESPIRATORY
  ilo_disease_category:
  - classification_value: pneumoconiosis_from_fibrogenic_mineral_dust
    notes: >-
      ILO List of Occupational Diseases (revised 2010), item 2.1.1
      "Pneumoconioses caused by fibrogenic mineral dust (silicosis,
      anthraco-silicosis, asbestosis)" — asbestosis is named in the item text.
      Asbestosis is the parenchymal fibrosis specifically; the asbestos-related
      malignancies take ILO section 3 items instead (see Malignant_Mesothelioma),
      which is the orthogonality between the ILO's organ-system and cancer
      sections rather than a contradiction.
  eu_occupational_category:
  - classification_value: asbestosis
    notes: >-
      European schedule of occupational diseases (Commission Recommendation
      2003/670/EC as amended), Annex I item 301.21 "Asbestosis". The European
      schedule separates asbestosis (301.21) from silicosis (301.11) where the
      ILO list folds both into item 2.1.1.
environmental:
- name: Occupational asbestos inhalation
  exposure_term:
    preferred_term: exposure to asbestos
    term:
      id: ECTO:9000033
      label: exposure to asbestos
  environment_context:
    preferred_term: asbestos dust
    term:
      id: ENVO:02000106
      label: asbestos dust
  chemicals:
  - asbestos
  exposure_classifications:
    hazard_agent_type:
    - classification_value: CHEMICAL
    exposure_route:
    - classification_value: INHALATION
      notes: >-
        Inhalation of airborne fibres is the route for asbestosis. Ingestion is
        the route implicated in the gastrointestinal cancers the European
        schedule added to its suspected list in 2025 (Annex II 2.309-2.311).
    exposure_duration:
    - classification_value: CHRONIC
      notes: >-
        ATSDR chronic duration (365 days and longer). Asbestosis is
        dose-dependent on cumulative fibre burden with a 15-40 year latency.
    iarc_carcinogen_group:
      classification_value: GROUP_1
      notes: >-
        IARC classifies all forms of asbestos as Group 1, carcinogenic to
        humans. Recorded on the exposure because it is a property of the agent:
        asbestosis is a fibrosis, not a cancer, and the Group 1 listing refers
        to the malignant outcomes of the same exposure (lung cancer,
        mesothelioma, laryngeal and ovarian cancer).
    ghs_health_hazard_class:
    - classification_value: CARCINOGENICITY
    - classification_value: STOT_REPEATED_EXPOSURE
      notes: >-
        The fibrotic lung injury of asbestosis is target-organ toxicity from
        repeated exposure, distinct from the carcinogenicity classification.
    exposome_domain:
    - classification_value: SPECIFIC_EXTERNAL
  description: >-
    Inhalation of airborne asbestos fibers during mining, milling, shipbuilding,
    insulation, construction, brake-lining, and textile work is the dominant
    exposure route. Both amphibole fibers (crocidolite, amosite) and, to a lesser
    fibrogenic degree, serpentine chrysotile can cause asbestosis; long, thin,
    biopersistent amphibole fibers are the most fibrogenic. Risk is
    dose-dependent (cumulative fiber burden) and paraoccupational/household and
    environmental exposures also occur.
  evidence:
  - reference: PMID:29772681
    reference_title: "Global Asbestos Disaster"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The first identified disease was asbestosis, a type of incurable pneumoconiosis caused by asbestos dust and fibres."
    explanation: Establishes asbestosis as an incurable pneumoconiosis caused by inhaled asbestos dust and fibers.
  - reference: PMID:36630203
    reference_title: "Asbestos-associated pulmonary disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "asbestos-related pulmonary complications include asbestosis, pleural plaques, diffuse pleural thickening, benign asbestos-related pleural effusions and malignant pleural mesothelioma"
    explanation: >-
      Places asbestosis within, and distinct from, the broader spectrum of
      asbestos-related pulmonary and pleural diseases, supporting the scope
      boundary stated in the description.
  - reference: PMID:38577971
    reference_title: "The asbestos-asbestosis exposure-response relationship: a cohort study of the general working population"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We found increasing incidence rate ratios (IRR) of asbestosis with increasing cumulative asbestos exposure with a fully adjusted IRR per 1 f/ml-years of 1.18"
    explanation: >-
      A large Danish general-working-population cohort demonstrates a
      dose-dependent exposure-response relationship between cumulative asbestos
      exposure and incident asbestosis.
  - reference: PMID:38192052
    reference_title: "The diagnosis of asbestosis in the 21(st) century: a clinicopathological correlation of 102 cases"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Asbestosis, defined as diffuse pulmonary fibrosis caused by inhalation of asbestos fibers, occurs after heavy exposures to asbestos dust over several decades."
    explanation: >-
      Modern clinicopathological series confirms the definition (diffuse
      pulmonary fibrosis from inhaled asbestos) and the multi-decade
      heavy-exposure requirement.
  influences_mechanisms:
  - target: Biopersistent asbestos fiber deposition
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      Inhalation of airborne fibers is what delivers them to the distal
      airspaces, so the retained biopersistent fiber burden scales with
      cumulative occupational exposure.
    evidence:
    - reference: PMID:38577971
      reference_title: "The asbestos-asbestosis exposure-response relationship: a cohort study of the general working population"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We found increasing incidence rate ratios (IRR) of asbestosis with increasing cumulative asbestos exposure with a fully adjusted IRR per 1 f/ml-years of 1.18"
      explanation: >-
        Disease incidence rises with cumulative fiber-years of exposure, the
        dose-response expected if inhaled exposure is what builds the retained
        fiber burden that initiates injury.
pathophysiology:
- name: Biopersistent asbestos fiber deposition
  biological_scale: TISSUE
  description: >-
    Inhaled asbestos fibers with a high length-to-width (aspect) ratio deposit at
    alveolar duct bifurcations and in the distal airspaces. Amphibole fibers
    (crocidolite, amosite) are cleared poorly and are retained for decades
    (biopersistence); over time host cells encase retained fibers in an
    iron-protein coat, forming ferruginous asbestos bodies. This retained,
    biopersistent fiber burden is the injurious insult that initiates the disease.
  conforms_to: "fibrotic_response#Tissue Injury"
  role: trigger
  cell_types:
  - preferred_term: alveolar macrophage
    term:
      id: CL:0000583
      label: alveolar macrophage
  - preferred_term: alveolar type I epithelial cell
    term:
      id: CL:0002062
      label: pulmonary alveolar type 1 cell
  - preferred_term: alveolar type II epithelial cell
    term:
      id: CL:0002063
      label: pulmonary alveolar type 2 cell
  locations:
  - preferred_term: lung
    term:
      id: UBERON:0002048
      label: lung
  evidence:
  - reference: PMID:37569765
    reference_title: "Asbestos and Iron"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "An inability to clear asbestos from the lower respiratory tract initiates a host process of iron biomineralization (i.e., asbestos body formation)."
    explanation: >-
      Supports biopersistence of retained fibers and iron-coated asbestos body
      formation as the hallmark of failed clearance.
  downstream:
  - target: Frustrated phagocytosis of asbestos fibers
- name: Frustrated phagocytosis of asbestos fibers
  biological_scale: CELLULAR
  description: >-
    Alveolar macrophages attempt to engulf the deposited fibers, but long fibers
    physically cannot be fully internalized. This "frustrated phagocytosis"
    leaves macrophages persistently activated and unable to clear the fiber,
    with leakage of lysosomal contents at the incomplete phagosome.
  role: driver
  cell_types:
  - preferred_term: alveolar macrophage
    term:
      id: CL:0000583
      label: alveolar macrophage
  biological_processes:
  - preferred_term: frustrated phagocytosis of asbestos fibers
    term:
      id: GO:0006909
      label: phagocytosis
    modifier: ABNORMAL
  evidence:
  - reference: PMID:37894824
    reference_title: "Distinct Pro-Inflammatory Mechanisms Elicited by Short and Long Amosite Asbestos Fibers in Macrophages"
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "the response to LFA was elicited by a multifactorial ignition system involving the macrophage receptor with collagenous structure (SR-A6 or MARCO), reactive oxygen species (ROS) cascade, and TLR4"
    explanation: >-
      In macrophage cultures, non-internalizable long amosite fibers trigger a
      distinct MARCO/ROS/TLR4 response, the signature of frustrated phagocytosis
      of long fibers.
  downstream:
  - target: Iron-catalyzed reactive oxygen species generation
- name: Iron-catalyzed reactive oxygen species generation
  biological_scale: MOLECULAR
  description: >-
    Iron adsorbed onto the fiber surface (and within asbestos bodies) plus
    macrophage superoxide produced at the phagosome membrane drive Fenton-type
    generation of hydroxyl radicals. The resulting reactive oxygen species
    directly injure alveolar epithelial DNA and membranes and activate
    redox-sensitive signaling.
  role: driver
  cell_types:
  - preferred_term: alveolar macrophage
    term:
      id: CL:0000583
      label: alveolar macrophage
  - preferred_term: alveolar type I epithelial cell
    term:
      id: CL:0002062
      label: pulmonary alveolar type 1 cell
  biological_processes:
  - preferred_term: reactive oxygen species generation
    term:
      id: GO:0072593
      label: reactive oxygen species metabolic process
    modifier: INCREASED
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
    modifier: INCREASED
  evidence:
  - reference: PMID:37569765
    reference_title: "Asbestos and Iron"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Host cells attempt to mobilize the metal sequestered by the fiber surface by producing superoxide at the phagosome membrane."
    explanation: >-
      Supports macrophage superoxide (reactive oxygen species) generation at the
      fiber-laden phagosome as the proximal oxidative-injury mechanism.
  downstream:
  - target: NLRP3 inflammasome activation
- name: NLRP3 inflammasome activation
  biological_scale: CELLULAR
  description: >-
    Asbestos fibers activate the NLRP3 inflammasome in alveolar macrophages,
    driving caspase-1-dependent maturation and release of IL-1beta and IL-18.
    Fiber-generated reactive oxygen species and lysosomal destabilization are
    upstream triggers of this sterile inflammasome response.
  role: driver
  cell_types:
  - preferred_term: alveolar macrophage
    term:
      id: CL:0000583
      label: alveolar macrophage
  biological_processes:
  - preferred_term: NLRP3 inflammasome complex assembly
    term:
      id: GO:0044546
      label: NLRP3 inflammasome complex assembly
    modifier: INCREASED
  evidence:
  - reference: PMID:21800904
    reference_title: "Long, needle-like carbon nanotubes and asbestos activate the NLRP3 inflammasome through a similar mechanism"
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "the NLRP3 inflammasome was essential for long, needle-like CNT and asbestos-induced IL-1β secretion"
    explanation: >-
      In human primary macrophages, asbestos-induced IL-1beta secretion requires
      the NLRP3 inflammasome.
  downstream:
  - target: Chronic sterile alveolitis
- name: Chronic sterile alveolitis
  biological_scale: TISSUE
  description: >-
    IL-1beta and IL-18 amplify recruitment and activation of macrophages and
    neutrophils in the distal lung, initiating a sterile inflammatory response
    that promotes the fibrotic program. Established histologic asbestosis may
    show little active inflammation, so this node represents the mediator phase
    rather than persistent inflammatory infiltrates in every case.
  conforms_to: "fibrotic_response#Inflammatory Recruitment and Amplification"
  role: driver
  cell_types:
  - preferred_term: alveolar macrophage
    term:
      id: CL:0000583
      label: alveolar macrophage
  - preferred_term: neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
    modifier: INCREASED
  evidence:
  - reference: PMID:37569765
    reference_title: "Asbestos and Iron"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "activates kinases and transcription factors, which are associated with the release of mediators coordinating both inflammatory and fibrotic responses"
    explanation: >-
      Links the fiber-triggered cellular response to mediators that coordinate the
      inflammatory alveolitis and its transition to fibrosis.
  downstream:
  - target: Pro-fibrotic mediator release
- name: Pro-fibrotic mediator release
  biological_scale: CELLULAR
  description: >-
    Activated macrophages and injured epithelial cells release pro-fibrotic
    growth factors - chiefly TGF-beta, plus PDGF, IGF-1, and fibronectin - that
    shift the chronic inflammatory response toward tissue remodeling. This
    mediator surge is the bridge from inflammation to mesenchymal activation.
    TGF-beta is the mediator with direct experimental support here: forced
    pulmonary TGF-beta1 expression is by itself sufficient to produce
    fibroproliferative lung disease. The accompanying PDGF, IGF-1, and
    fibronectin claims are drawn from the wider fibrosis literature and are not
    separately evidenced in this entry.
  role: driver
  cell_types:
  - preferred_term: alveolar macrophage
    term:
      id: CL:0000583
      label: alveolar macrophage
  biological_processes:
  - preferred_term: transforming growth factor beta production
    term:
      id: GO:0071604
      label: transforming growth factor beta production
    modifier: INCREASED
  evidence:
  - reference: PMID:12444030
    reference_title: "Susceptibility to asbestos-induced and transforming growth factor-beta1-induced fibroproliferative lung disease in two strains of mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "both strains of mice were treated intratracheally with an adenovirus vector (AdV), which transduces expression of active transforming growth factor (TGF)-beta(1) in the lungs, producing fibroproliferative lung disease"
    explanation: "Pulmonary TGF-beta1 expression alone produces fibroproliferative lung disease in mice, supporting TGF-beta release as the mediator bridging inflammation to the fibrotic response."
  - reference: PMID:37569765
    reference_title: Asbestos and Iron.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "activates kinases and transcription factors, which are associated with the release of mediators coordinating both inflammatory and fibrotic responses"
    explanation: "Review places mediator release downstream of the fiber-triggered cell response and upstream of the coordinated inflammatory and fibrotic programs. Evidence source OTHER (review)."
  - reference: PMID:23463177
    reference_title: "Altered functions of alveolar macrophages and NK cells involved in asbestos-related diseases."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Exposure to asbestos caused rat AM to exhibit high production of transforming growth factor-beta (TGF-β) with prolonged survival in the absence of other cells"
    explanation: Asbestos-exposed rat alveolar macrophages directly produced high TGF-beta.
  downstream:
  - target: Myofibroblast differentiation
- name: Myofibroblast differentiation
  biological_scale: CELLULAR
  description: >-
    TGF-beta recruits fibroblasts to the injured interstitium and drives their
    differentiation into contractile, matrix-secreting alpha-SMA-positive
    myofibroblasts. This mesenchymal activation is the proximate cellular driver
    of matrix accumulation.
  conforms_to: "fibrotic_response#Mesenchymal Cell Activation"
  role: driver
  cell_types:
  - preferred_term: lung fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  - preferred_term: myofibroblast
    term:
      id: CL:0000186
      label: myofibroblast cell
  biological_processes:
  - preferred_term: fibroblast migration
    term:
      id: GO:0010761
      label: fibroblast migration
    modifier: INCREASED
  - preferred_term: TGF-beta receptor signaling
    term:
      id: GO:0007179
      label: transforming growth factor beta receptor signaling pathway
    modifier: INCREASED
  - preferred_term: myofibroblast differentiation
    term:
      id: GO:0036446
      label: myofibroblast differentiation
    modifier: INCREASED
  evidence:
  - reference: PMID:12444030
    reference_title: "Susceptibility to asbestos-induced and transforming growth factor-beta1-induced fibroproliferative lung disease in two strains of mice"
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "both strains of mice were treated intratracheally with an adenovirus vector (AdV), which transduces expression of active transforming growth factor (TGF)-beta(1) in the lungs, producing fibroproliferative lung disease"
    explanation: >-
      In a mouse model, lung TGF-beta1 expression is sufficient to produce
      fibroproliferative lung disease, supporting TGF-beta-driven
      fibroblast-to-myofibroblast activation.
  downstream:
  - target: Excessive extracellular matrix deposition
- name: Excessive extracellular matrix deposition
  biological_scale: TISSUE
  description: >-
    Activated myofibroblasts deposit excess type I collagen and other matrix
    components in the alveolar walls and interstitium, beginning around
    respiratory bronchioles and extending into the alveolar interstitium. The
    accumulated matrix is what makes asbestosis a diffuse fibrosing parenchymal
    disease; the specific collagen subtype and the bronchiolocentric starting
    point are drawn from the wider pathology literature rather than from a
    source curated in this entry.
  conforms_to: "fibrotic_response#Excessive ECM Deposition"
  role: driver
  cell_types:
  - preferred_term: myofibroblast
    term:
      id: CL:0000186
      label: myofibroblast cell
  biological_processes:
  - preferred_term: collagen fibril organization
    term:
      id: GO:0030199
      label: collagen fibril organization
    modifier: INCREASED
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
    modifier: ABNORMAL
  evidence:
  - reference: PMID:38192052
    reference_title: "The diagnosis of asbestosis in the 21(st) century: a clinicopathological correlation of 102 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Asbestosis, defined as diffuse pulmonary fibrosis caused by inhalation of asbestos fibers, occurs after heavy exposures to asbestos dust over several decades."
    explanation: "Diffuse pulmonary fibrosis - the accumulated matrix this node deposits - is the defining lesion in a 102-case clinicopathological series."
  - reference: PMID:32553000
    reference_title: Asbestos-related diseases.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Deposition in the lung parenchyma results in an inflammatory/progressively fibrotic response, with impaired gas exchange and reduced lung compliance ('asbestosis')"
    explanation: "Review links parenchymal fiber deposition to the progressive fibrotic (matrix-accumulating) response that defines asbestosis. Evidence source OTHER (review)."
  - reference: PMID:3004226
    reference_title: "Crocidolite-induced pulmonary fibrosis in mice. Cytokinetic and biochemical studies."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Increased collagen levels were largely due to stimulation of peribronchial fibroblasts."
    explanation: A mouse crocidolite-instillation model links fibroblast stimulation to increased pulmonary collagen.
  downstream:
  - target: Interstitial fibrosis and architectural distortion
- name: Interstitial fibrosis and architectural distortion
  biological_scale: TISSUE
  description: >-
    Accumulating matrix thickens the air-blood barrier and produces
    lower-zone-predominant interstitial fibrosis, progressively obliterating
    normal alveolar architecture with honeycombing in advanced disease. This is
    the defining parenchymal lesion of asbestosis.
  conforms_to: "fibrotic_response#Architectural Distortion and Organ Dysfunction"
  role: outcome
  locations:
  - preferred_term: lung
    term:
      id: UBERON:0002048
      label: lung
  biological_processes:
  - preferred_term: wound healing
    term:
      id: GO:0042060
      label: wound healing
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:38192052
    reference_title: "The diagnosis of asbestosis in the 21(st) century: a clinicopathological correlation of 102 cases"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Asbestosis, defined as diffuse pulmonary fibrosis caused by inhalation of asbestos fibers, occurs after heavy exposures to asbestos dust over several decades."
    explanation: >-
      Confirms diffuse interstitial pulmonary fibrosis as the defining structural
      lesion of asbestosis.
  downstream:
  - target: Restrictive ventilatory failure
  - target: Diffuse interstitial pulmonary fibrosis
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:38192052
      reference_title: "The diagnosis of asbestosis in the 21(st) century: a clinicopathological correlation of 102 cases"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Asbestosis, defined as diffuse pulmonary fibrosis caused by inhalation of asbestos fibers, occurs after heavy exposures to asbestos dust over several decades."
      explanation: The defining tissue lesion directly reports as the pulmonary-fibrosis phenotype.
  - target: Inspiratory crackles
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Abrupt opening of fibrotic distal airways during late inspiration
    evidence:
    - reference: PMID:464386
      reference_title: "Absence of synergism between exposure to asbestos and cigarette smoking in asbestosis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "bilateral fine crackles, clubbing, dyspnea, radiographic abnormality, decreased forced vital capacity, and decreased single-breath diffusing capacity of the lung for CO"
      explanation: Bilateral fine crackles are a documented manifestation of the fibrotic lung lesion.
- name: Restrictive ventilatory failure
  biological_scale: ORGANISM
  description: >-
    Loss of lung compliance and impaired gas exchange from the interstitial
    fibrosis produce a restrictive ventilatory defect with reduced diffusing
    capacity and chronic hypoxemia, progressing in advanced disease to pulmonary
    hypertension, cor pulmonale, and respiratory failure.
  role: outcome
  locations:
  - preferred_term: lung
    term:
      id: UBERON:0002048
      label: lung
  evidence:
  - reference: PMID:32553000
    reference_title: "Asbestos-related diseases"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Deposition in the lung parenchyma results in an inflammatory/progressively fibrotic response, with impaired gas exchange and reduced lung compliance ('asbestosis')"
    explanation: >-
      Confirms the terminal physiologic outcome: impaired gas exchange and reduced
      lung compliance (restrictive physiology).
  downstream:
  - target: Exertional dyspnea
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Reduced compliance, impaired diffusion, and exertional gas-exchange limitation
    evidence:
    - reference: PMID:32553000
      reference_title: "Asbestos-related diseases"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "causing progressive dyspnoea and respiratory failure for which only palliation is indicated"
      explanation: The review links fibrotic physiologic impairment to progressive dyspnea.
  - target: Restrictive ventilatory defect
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:32553000
      reference_title: "Asbestos-related diseases"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "impaired gas exchange and reduced lung compliance ('asbestosis')"
      explanation: Reduced compliance is the direct physiologic basis of a restrictive defect.
  - target: Decreased DLCO
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:464386
      reference_title: "Absence of synergism between exposure to asbestos and cigarette smoking in asbestosis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "bilateral fine crackles, clubbing, dyspnea, radiographic abnormality, decreased forced vital capacity, and decreased single-breath diffusing capacity of the lung for CO"
      explanation: An asbestos-exposed worker study identifies reduced diffusing capacity as an asbestosis manifestation.
  - target: Reduced forced vital capacity
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:464386
      reference_title: "Absence of synergism between exposure to asbestos and cigarette smoking in asbestosis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "bilateral fine crackles, clubbing, dyspnea, radiographic abnormality, decreased forced vital capacity, and decreased single-breath diffusing capacity of the lung for CO"
      explanation: Restrictive physiology directly reduces forced vital capacity.
  - target: Respiratory failure
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:32553000
      reference_title: "Asbestos-related diseases"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "causing progressive dyspnoea and respiratory failure for which only palliation is indicated"
      explanation: Advanced physiologic impairment directly manifests as respiratory failure.
phenotypes:
- name: Exertional dyspnea
  description: Progressive breathlessness on exertion is the cardinal symptom.
  phenotype_term:
    preferred_term: Exertional dyspnea
    term:
      id: HP:0002875
      label: Exertional dyspnea
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:32553000
    reference_title: "Asbestos-related diseases"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "causing progressive dyspnoea and respiratory failure for which only palliation is indicated"
    explanation: >-
      Review identifies progressive dyspnea (advancing to respiratory failure) as
      the defining clinical consequence of the asbestosis fibrotic response.
  - reference: ORPHA:2302
    reference_title: Asbestos intoxication
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Symptoms may appear many years after exposure and include progressive dyspnea on exertion, dry cough, chest pain, tightness, inspiratory crackles, clubbing of the fingers."
    explanation: Orphanet explicitly identifies progressive dyspnea on exertion.
- name: Inspiratory crackles
  description: Inspiratory crackles; fine and bilateral in one worker cohort.
  phenotype_term:
    preferred_term: Inspiratory crackles
    term:
      id: HP:0031996
      label: Inspiratory crackles
  evidence:
  - reference: PMID:464386
    reference_title: "Absence of synergism between exposure to asbestos and cigarette smoking in asbestosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "bilateral fine crackles, clubbing, dyspnea, radiographic abnormality, decreased forced vital capacity, and decreased single-breath diffusing capacity of the lung for CO"
    explanation: Bilateral fine crackles were a standardized clinical manifestation in asbestos-exposed workers.
  - reference: ORPHA:2302
    reference_title: Asbestos intoxication
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Symptoms may appear many years after exposure and include progressive dyspnea on exertion, dry cough, chest pain, tightness, inspiratory crackles, clubbing of the fingers."
    explanation: Orphanet explicitly identifies inspiratory crackles.
- name: Nonproductive cough
  description: Dry cough can accompany the chronic fibrotic respiratory syndrome.
  phenotype_term:
    preferred_term: Nonproductive cough
    term:
      id: HP:0031246
      label: Nonproductive cough
  evidence:
  - reference: ORPHA:2302
    reference_title: Asbestos intoxication
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Symptoms may appear many years after exposure and include progressive dyspnea on exertion, dry cough, chest pain, tightness, inspiratory crackles, clubbing of the fingers."
    explanation: Orphanet lists dry cough among asbestosis symptoms.
- name: Diffuse interstitial pulmonary fibrosis
  description: >-
    Bilateral, lower-zone-predominant interstitial fibrosis is the defining
    parenchymal lesion of asbestosis.
  phenotype_term:
    preferred_term: Bilateral basilar pulmonary fibrosis
    term:
      id: HP:0550005
      label: Bilateral basilar pulmonary fibrosis
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:38192052
    reference_title: "The diagnosis of asbestosis in the 21(st) century: a clinicopathological correlation of 102 cases"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Asbestosis, defined as diffuse pulmonary fibrosis caused by inhalation of asbestos fibers, occurs after heavy exposures to asbestos dust over several decades."
    explanation: >-
      Confirms diffuse pulmonary fibrosis as the defining parenchymal lesion of
      asbestosis.
- name: Restrictive ventilatory defect
  description: >-
    Reduced lung volumes and diffusing capacity on pulmonary function testing.
  phenotype_term:
    preferred_term: Restrictive ventilatory defect
    term:
      id: HP:0002091
      label: Restrictive ventilatory defect
  evidence:
  - reference: PMID:32553000
    reference_title: "Asbestos-related diseases"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "impaired gas exchange and reduced lung compliance ('asbestosis')"
    explanation: >-
      Reduced lung compliance and impaired gas exchange are the physiologic
      hallmark of the restrictive defect in asbestosis.
- name: Digital clubbing
  description: Clubbing of the fingers in more advanced disease.
  phenotype_term:
    preferred_term: Clubbing of fingers
    term:
      id: HP:0100759
      label: Clubbing of fingers
  evidence:
  - reference: PMID:9230732
    reference_title: "Clinical predictors of mortality from asbestosis in the North American Insulator Cohort, 1981 to 1991."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dyspnea, a low FVC, and/or physical examination findings typical of interstitial fibrosis (rales, clubbing, or cyanosis) raised the risk of subsequent death from asbestosis by 2- to 6-fold."
    explanation: Clubbing was documented as a clinical sign and adverse prognostic marker in a large insulator cohort.
- name: Decreased DLCO
  description: Reduced single-breath diffusing capacity due to thickening and destruction of the gas-exchange interface.
  phenotype_term:
    preferred_term: Decreased DLCO
    term:
      id: HP:0045051
      label: Decreased DLCO
  evidence:
  - reference: PMID:464386
    reference_title: "Absence of synergism between exposure to asbestos and cigarette smoking in asbestosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "bilateral fine crackles, clubbing, dyspnea, radiographic abnormality, decreased forced vital capacity, and decreased single-breath diffusing capacity of the lung for CO"
    explanation: Reduced diffusing capacity was measured as a manifestation in asbestos-exposed workers.
- name: Reduced forced vital capacity
  description: Reduced FVC is a common restrictive physiologic manifestation and a longitudinal progression measure.
  phenotype_term:
    preferred_term: Reduced forced vital capacity
    term:
      id: HP:0032341
      label: Reduced forced vital capacity
  evidence:
  - reference: PMID:464386
    reference_title: "Absence of synergism between exposure to asbestos and cigarette smoking in asbestosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "bilateral fine crackles, clubbing, dyspnea, radiographic abnormality, decreased forced vital capacity, and decreased single-breath diffusing capacity of the lung for CO"
    explanation: Reduced FVC was measured in standardized examinations of asbestos-exposed workers.
- name: Respiratory failure
  description: Advanced asbestosis can culminate in hypoxemic respiratory failure.
  phenotype_term:
    preferred_term: Respiratory failure
    term:
      id: HP:0002878
      label: Respiratory failure
    severity: SEVERE
  evidence:
  - reference: PMID:32553000
    reference_title: "Asbestos-related diseases"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "causing progressive dyspnoea and respiratory failure for which only palliation is indicated"
    explanation: Review explicitly identifies respiratory failure as an advanced consequence.
histopathology:
- name: Diffuse interstitial fibrosis with asbestos (ferruginous) bodies
  description: >-
    The diagnostic histologic lesion is diffuse interstitial fibrosis in the
    appropriate anatomic distribution together with identifiable asbestos
    (ferruginous) bodies - golden-brown, beaded, iron-protein-coated fibers - or
    a documented elevated lung fiber burden. Amphibole fibers (especially
    amosite) predominate in fiber-burden analyses, and pleural plaques commonly
    coexist as a marker of exposure.
  diagnostic: true
  evidence:
  - reference: PMID:38192052
    reference_title: "The diagnosis of asbestosis in the 21(st) century: a clinicopathological correlation of 102 cases"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lung fiber burden analysis was performed in 34 cases, with amosite being the predominant fiber type."
    explanation: >-
      Amphibole (amosite) fibers predominate in the retained lung fiber burden of
      pathologically confirmed asbestosis cases.
  - reference: PMID:38192052
    reference_title: "The diagnosis of asbestosis in the 21(st) century: a clinicopathological correlation of 102 cases"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pleural plaque was present in 94% of cases."
    explanation: >-
      Pleural plaques frequently coexist with parenchymal asbestosis as a marker
      of prior asbestos exposure, though they are a separate lesion.
diagnosis:
- name: Exposure history and high-resolution chest CT correlation
  description: >-
    Diagnosis requires a credible asbestos exposure with appropriate latency,
    compatible bilateral basal/subpleural fibrosis on HRCT, and exclusion of a
    better explanation. Pleural plaques support prior exposure but are neither
    necessary nor sufficient for parenchymal asbestosis.
  diagnosis_term:
    preferred_term: High-resolution chest computed tomography
    term:
      id: NCIT:C17204
      label: Computed Tomography
  results: >-
    Basal/subpleural interstitial fibrosis; subpleural dots, short subpleural
    lines, and parenchymal bands favor asbestosis over idiopathic pulmonary fibrosis.
  evidence:
  - reference: PMID:26901505
    reference_title: "The comparison of high-resolution computed tomography findings in asbestosis and idiopathic pulmonary fibrosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "On multivariate analysis, HRCT features that distinguished asbestosis from IPF were subpleural lines at a distance of less than 5 mm from the inner chest wall, subpleural dots and parenchymal bands."
    explanation: Comparative imaging study identifies HRCT features useful in the principal differential.
- name: Pulmonary function testing
  description: >-
    Spirometry, lung volumes, and DLCO establish physiologic impairment and
    provide longitudinal severity/progression measures; they support but do not
    establish asbestos causation.
  diagnosis_term:
    preferred_term: Pulmonary Function Test
    term:
      id: NCIT:C38081
      label: Pulmonary Function Test
  results: Restriction, reduced forced vital capacity, and reduced diffusing capacity.
  evidence:
  - reference: PMID:464386
    reference_title: "Absence of synergism between exposure to asbestos and cigarette smoking in asbestosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "bilateral fine crackles, clubbing, dyspnea, radiographic abnormality, decreased forced vital capacity, and decreased single-breath diffusing capacity of the lung for CO"
    explanation: Standardized worker examinations document the characteristic functional abnormalities.
- name: Lung biopsy and quantitative fiber burden when noninvasive evaluation is indeterminate
  description: >-
    Tissue is not routinely required, but in disputed or atypical cases the
    combination of appropriate interstitial fibrosis and excess asbestos bodies
    or quantitative fiber burden can establish pathologic attribution.
  diagnosis_term:
    preferred_term: Lung Biopsy
    term:
      id: NCIT:C51748
      label: Lung Biopsy
  results: Appropriate fibrosis plus evidence of excess pulmonary asbestos burden.
  evidence:
  - reference: PMID:20196674
    reference_title: "Pathology of asbestosis- An update of the diagnostic criteria: Report of the asbestosis committee of the college of american pathologists and pulmonary pathology society."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Two or more asbestos bodies per square centimeter of a 5- mu m-thick lung section, in combination with interstitial fibrosis of the appropriate pattern, are indicative of asbestosis."
    explanation: Consensus pathology criteria define a tissue asbestos-body threshold with compatible fibrosis.
differential_diagnoses:
- name: Idiopathic pulmonary fibrosis
  disease_term:
    preferred_term: idiopathic pulmonary fibrosis
    term:
      id: MONDO:0800504
      label: idiopathic pulmonary fibrosis
  description: Both disorders can show basal, subpleural fibrosis with a UIP-like pattern.
  distinguishing_features:
  - >-
    A credible high cumulative asbestos exposure, pleural fibrosis/plaques,
    asbestos bodies or elevated lung fiber burden, and subpleural dots/lines or
    parenchymal bands favor asbestosis. Fibroblastic foci and active inflammation
    are more characteristic of IPF.
  evidence:
  - reference: PMID:20196674
    reference_title: "Pathology of asbestosis- An update of the diagnostic criteria: Report of the asbestosis committee of the college of american pathologists and pulmonary pathology society."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The pulmonary fibrosis of asbestosis is interstitial and has a basal subpleural distribution, similar to that seen in idiopathic pulmonary fibrosis, which is the principal differential diagnosis."
    explanation: Consensus review explicitly identifies IPF as the principal differential.
- name: Mixed dust pneumoconiosis and smoking-related respiratory bronchiolitis
  disease_term:
    preferred_term: mixed dust pneumoconiosis
  description: Early centriacinar/peribronchiolar fibrosis overlaps with mixed-dust and smoking-related lesions.
  distinguishing_features:
  - >-
    Fibrosis confined to bronchiolar walls is insufficient for asbestosis;
    diffuse acinar extension plus evidence of excess asbestos burden is required.
  evidence:
  - reference: PMID:20196674
    reference_title: "Pathology of asbestosis- An update of the diagnostic criteria: Report of the asbestosis committee of the college of american pathologists and pulmonary pathology society."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Fibrosis limited to the walls of the bronchioles does not represent asbestosis."
    explanation: Consensus criteria prevent overcalling nonspecific bronchiolar fibrosis as asbestosis.
genetic:
- name: GSTM1
  gene_term:
    preferred_term: GSTM1
    term:
      id: hgnc:4632
      label: GSTM1
  association: >-
    Homozygous GSTM1 (glutathione S-transferase mu-1) deletion / null genotype
    has been proposed as a gene-environment susceptibility modifier for
    nonmalignant asbestos-related disease, plausibly by reducing detoxification
    of fiber-generated reactive electrophiles and oxidants. The evidence is
    conflicting: an early cross-sectional study found increased risk, whereas a
    later, larger nested case-control study found no GSTM1 association.
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  evidence:
  - reference: PMID:8000297
    reference_title: "Inherited glutathione-S-transferase deficiency is a risk factor for pulmonary asbestosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Individuals genetically deficient in GST-mu were significantly more likely to have radiographic evidence of nonmalignant asbestos-related disease than those who were not deficient"
    explanation: >-
      In asbestos-exposed carpenters, homozygous GSTM1 deletion was associated
      with radiographic nonmalignant asbestos-related disease, but the snippet
      does not isolate pathologically confirmed asbestosis and later evidence
      was null; it therefore only partially supports an asbestosis modifier.
  - reference: PMID:17563610
    reference_title: "Glutathione S-transferases GSTM1 and GSTT1 polymorphisms and asbestosis."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "but not with GSTM1-null genotype (OR=1.01, CI 0.71-1.43)"
    explanation: >-
      A larger nested case-control study found no association between the
      GSTM1-null genotype and asbestosis, conflicting with the earlier report.
  notes: >-
    GSTM1 encodes a phase II detoxification enzyme; roughly half of individuals
    of European ancestry carry a homozygous deletion. Its role in asbestosis
    susceptibility remains unsettled.
- name: GSTT1
  gene_term:
    preferred_term: GSTT1
    term:
      id: hgnc:4641
      label: GSTT1
  association: >-
    In a nested case-control study, the GSTT1 (glutathione S-transferase
    theta-1) null genotype was associated with a reduced risk of asbestosis (a
    protective effect), independent of cumulative exposure.
  relationship_type: PROTECTIVE
  variant_origin: GERMLINE
  evidence:
  - reference: PMID:17563610
    reference_title: "Glutathione S-transferases GSTM1 and GSTT1 polymorphisms and asbestosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "GSTT1 gene deletion might have a protective effect on the development of asbestosis"
    explanation: >-
      The study concluded that the GSTT1-null genotype may protect against the
      development of asbestosis.
  notes: >-
    A gene-environment interaction; the protective association was reported
    independent of cumulative asbestos exposure, smoking, sex, and age.
treatments:
- name: Smoking cessation
  description: >-
    Smoking cessation is strongly advised because tobacco smoke and asbestos act
    multiplicatively to increase lung cancer risk.
  treatment_term:
    preferred_term: smoking cessation
    term:
      id: NCIT:C15372
      label: Smoking Cessation Intervention
  evidence:
  - reference: PMID:32553000
    reference_title: "Asbestos-related diseases"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Bronchogenic carcinoma risk from asbestos exposure is dose-dependent and multiplies the risk attributable to tobacco smoking."
    explanation: >-
      The multiplicative interaction between asbestos and tobacco on lung cancer
      risk is the rationale for prioritizing smoking cessation in asbestos-exposed
      patients.
- name: Supplemental oxygen therapy
  description: Long-term oxygen for chronic hypoxemia in advanced disease.
  treatment_term:
    preferred_term: supplemental oxygen therapy
    term:
      id: NCIT:C94624
      label: Oxygen Therapy
  evidence:
  - reference: PMID:32553000
    reference_title: Asbestos-related diseases.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "causing progressive dyspnoea and respiratory failure for which only palliation is indicated"
    explanation: "Supports palliative/supportive management (of which supplemental oxygen is a component) as the available approach for progressive dyspnoea and respiratory failure. Marked PARTIAL: the review does not name oxygen therapy specifically. Evidence source OTHER (review)."
- name: Pulmonary rehabilitation
  description: >-
    Structured exercise and education to improve exertional capacity and quality
    of life.
  treatment_term:
    preferred_term: pulmonary rehabilitation
    term:
      id: NCIT:C157966
      label: Pulmonary Rehabilitation
  evidence:
  - reference: PMID:32053838
    reference_title: "[Sustainability in Outpatient Pulmonary Rehabilitation in Patients with Asbestosis - Results of an 8-Year Follow Up]"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "specific exercise therapy and sports are able to mobilize physical reserves of performance and induce an increasing quality of life as well as a higher resilience in activities of daily living"
    explanation: >-
      An 8-year follow-up of outpatient pulmonary rehabilitation in asbestosis
      patients shows exercise therapy improves quality of life and daily-living
      resilience despite the irreversible restrictive disease.
- name: Lung transplantation
  description: Considered in selected patients with end-stage fibrosis.
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: NCIT:C15289
      label: Organ Transplantation
- name: Removal from ongoing asbestos exposure
  description: >-
    Ending further asbestos exposure is a cardinal management step. Because
    asbestosis risk is dose-dependent on cumulative fiber burden, halting
    additional exposure limits further accrual of injurious fiber load. It does
    not reverse established fibrosis (retained fibers are biopersistent), so it
    is preventive of progression rather than curative.
  evidence:
  - reference: PMID:38577971
    reference_title: "The asbestos-asbestosis exposure-response relationship: a cohort study of the general working population"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We found increasing incidence rate ratios (IRR) of asbestosis with increasing cumulative asbestos exposure with a fully adjusted IRR per 1 f/ml-years of 1.18"
    explanation: >-
      The dose-dependent cumulative-exposure relationship is the rationale for
      removal from further asbestos exposure to limit additional risk.
- name: Vaccination
  description: >-
    Influenza and pneumococcal vaccination are recommended supportive measures
    to reduce respiratory infections that can precipitate acute decompensation
    in chronic fibrotic lung disease.
  treatment_term:
    preferred_term: vaccination
    term:
      id: NCIT:C15346
      label: Vaccination
- name: Pirfenidone
  description: >-
    Investigational antifibrotic therapy for progressive asbestosis. A
    10-patient prospective safety study found acceptable tolerability but no
    significant change in hospital PFTs, and a later real-world
    analysis found only modest, statistically non-significant changes in FVC and
    DLCO decline. It is not established disease-modifying standard therapy.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: pirfenidone
      term:
        id: CHEBI:32016
        label: pirfenidone
  evidence:
  - reference: PMID:35643466
    reference_title: "Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "No significant changes in hospital pulmonary function (forced vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLCO), 6 min walking test or patient-reported outcomes measures before and after start of pirfenidone were found."
    explanation: Small prospective study supports feasibility and safety but not established efficacy.
  - reference: PMID:41438854
    reference_title: "The effect of pirfenidone on disease progression in asbestosis patients: a real-world Dutch cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Findings based on asbestosis patients treated between 2004 and 2024 reveal a modest reduction in the rate of FVC decline (mean (95% CI) difference 7.0 (-5.8-19.7) mL·month-1, p=0.22) and D LCO decline (0.11% (-0.19-0.41%), p=0.30) after starting pirfenidone"
    explanation: Real-world before/after estimates are compatible with modest benefit but are imprecise and non-significant.
animal_models:
- species: Rat (Rattus norvegicus)
  category: Induced inhalation model
  description: >-
    Brief aerosolized chrysotile exposure produces deposition at first alveolar
    duct bifurcations, macrophage accumulation, TGF-beta localization, and early
    fibronectin/alpha-smooth-muscle-actin-positive fibrogenic lesions. It models
    early spatial events but compresses decades of human latency.
  associated_phenotypes:
  - Pulmonary interstitial fibrosis
  evidence:
  - reference: PMID:8027525
    reference_title: "Distribution of transforming growth factor-beta 1, fibronectin, and smooth muscle actin in asbestos-induced pulmonary fibrosis in rats."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These sites, the first alveolar duct bifurcations, are where the fibers are initially deposited and where macrophages first accumulate."
    explanation: Defines the spatially resolved rat inhalation model and its earliest cellular events.
- species: Mouse (Mus musculus)
  category: Induced intratracheal instillation model
  description: >-
    Intratracheal crocidolite causes epithelial injury, sustained alveolar
    macrophage accumulation, fibroblast stimulation, and increased collagen over
    a 20-week course. Bolus instillation does not reproduce human aerosol dose,
    fiber clearance, or latency.
  associated_phenotypes:
  - Pulmonary interstitial fibrosis
  evidence:
  - reference: PMID:3004226
    reference_title: "Crocidolite-induced pulmonary fibrosis in mice. Cytokinetic and biochemical studies."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The lesions were induced by intratracheal instillation of 1 mg crocidolite asbestos in mice, which were killed up to 20 weeks thereafter"
    explanation: Establishes the induced mouse model, exposure method, dose, and study duration.
experimental_models:
- name: Asbestos-exposed macrophage culture
  experimental_model_type: PRIMARY_CELL_CULTURE
  cell_source: Murine macrophages
  culture_system: In-vitro fiber exposure
  description: >-
    Macrophage cultures expose cells to defined fiber lengths to resolve
    phagocytosis, ROS, TLR4/MARCO signaling, inflammasome activation, cytokine
    release, and death programs. The model lacks epithelial-mesenchymal and
    clearance dynamics of the intact human lung.
  modeled_mechanisms:
  - target: Frustrated phagocytosis of asbestos fibers
    description: Resolves fiber-length-dependent uptake failure and macrophage signaling.
    evidence:
    - reference: PMID:37894824
      reference_title: "Distinct Pro-Inflammatory Mechanisms Elicited by Short and Long Amosite Asbestos Fibers in Macrophages"
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "macrophage responses to non-internalizable LFA were associated with tumor necrosis factor alpha (TNF-α) release, caspase-3 and -7 activation, and apoptosis"
      explanation: Long fibers were non-internalizable and elicited macrophage signaling, supporting uptake failure without explicitly naming frustrated phagocytosis.
  - target: NLRP3 inflammasome activation
    description: Measures inflammasome-dependent cytokine release after fiber exposure.
    evidence:
    - reference: PMID:37894824
      reference_title: "Distinct Pro-Inflammatory Mechanisms Elicited by Short and Long Amosite Asbestos Fibers in Macrophages"
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "SFA internalization resulted in pyroptotic-related immunogenic cell death (ICD) characterized by the release of the pro-inflammatory damage signal (DAMP) IL-1α after inflammasome activation and gasdermin D (GSDMD)-pore formation."
      explanation: Short-fiber internalization activated an inflammasome and pyroptotic signaling, but the abstract does not identify NLRP3 specifically.
  publication: PMID:37894824
  evidence:
  - reference: PMID:37894824
    reference_title: "Distinct Pro-Inflammatory Mechanisms Elicited by Short and Long Amosite Asbestos Fibers in Macrophages"
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "the response to LFA was elicited by a multifactorial ignition system involving the macrophage receptor with collagenous structure (SR-A6 or MARCO), reactive oxygen species (ROS) cascade, and TLR4"
    explanation: Defines the long-fiber macrophage signaling phenotype reproduced in vitro.
clinical_trials:
- name: NCT05133453
  phase: NOT_APPLICABLE
  status: UNKNOWN
  description: >-
    Registry-listed study of pirfenidone efficacy and prognosis in
    clinically and radiologically defined asbestosis. The cached registry record
    reports unknown status and no posted results; no efficacy inference is made.
  target_phenotypes:
  - preferred_term: Reduced forced vital capacity
    term:
      id: HP:0032341
      label: Reduced forced vital capacity
  evidence:
  - reference: clinicaltrials:NCT05133453
    reference_title: "Pirfenidone Use in Asbestosis Patients: Efficacy and Prognosis"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study aims at determining the the efficiency and prognosis of using pirfenidone drug among asbestosis patients."
    explanation: Trial registry summary establishes the asbestosis-specific pirfenidone study objective only.
discussions:
- discussion_id: gap_asbestosis_antifibrotic_efficacy
  prompt: Do pirfenidone or other antifibrotic drugs produce a clinically meaningful benefit in progressive asbestosis?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Excessive extracellular matrix deposition
  - treatments#Pirfenidone
  rationale: >-
    Available asbestosis-specific studies are small and uncontrolled or
    real-world before/after analyses; estimates are imprecise, and no adequately
    powered randomized disease-specific efficacy trial has established benefit.
  evidence:
  - reference: PMID:41438854
    reference_title: "The effect of pirfenidone on disease progression in asbestosis patients: a real-world Dutch cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Findings based on asbestosis patients treated between 2004 and 2024 reveal a modest reduction in the rate of FVC decline (mean (95% CI) difference 7.0 (-5.8-19.7) mL·month-1, p=0.22) and D LCO decline (0.11% (-0.19-0.41%), p=0.30) after starting pirfenidone"
    explanation: The latest asbestosis-specific cohort remains statistically inconclusive.
- discussion_id: mismatch_asbestosis_bolus_and_short_term_models
  prompt: How faithfully do bolus-instilled and short-duration rodent asbestos models reproduce chronic human fiber retention and decades-long asbestosis?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Biopersistent asbestos fiber deposition
  - pathophysiology#Excessive extracellular matrix deposition
  rationale: >-
    Rodent models reproduce deposition, macrophage recruitment, TGF-beta
    signaling, and collagen deposition, but their delivery route, dose, lung
    anatomy, clearance kinetics, and compressed timescale differ materially from
    chronic occupational inhalation in humans.
  evidence:
  - reference: PMID:3004226
    reference_title: "Crocidolite-induced pulmonary fibrosis in mice. Cytokinetic and biochemical studies."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The lesions were induced by intratracheal instillation of 1 mg crocidolite asbestos in mice, which were killed up to 20 weeks thereafter"
    explanation: The experimental exposure and timescale document the central translational mismatch.
datasets:
- accession: geo:GSE6013
  title: Gene expression in asbestos exposed lung cells
  description: Asbestos has been shown to cause chromosomal damage and DNA aberrations. The fiber is associated with many different lung diseases such as asbestosis, malignant mesothelioma, and lung cancer, but the disease-related processes are still largely unknown. Our aim was to identify specific gene expression profiles by using Affymetrix arrays, in human cell lines A549, Beas-2B, and MeT5A exposed to asbestos in a time-dependent manner.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: MICROARRAY
  sample_count: 27
  publication: PMID:17331233
  notes: Identified by GEO DataSets index search for Asbestosis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.

📚

References & Deep Research

Deep Research

1

Claude Code ▸

1. Disease Information

claude-haiku-4-5-20251001, claude-opus-4-8 20 citations 2026-07-16T18:47:22.885601

1. Disease Information

Overview. Asbestosis is a chronic, progressive, diffuse interstitial pulmonary fibrosis (pneumoconiosis) caused by the inhalation and lung retention of asbestos mineral fibers. It is the fibrotic parenchymal lung disease specifically attributable to asbestos, distinct from asbestos-related pleural disease (pleural plaques, diffuse pleural thickening, benign asbestos pleural effusion) and from asbestos-associated malignancies (bronchogenic carcinoma, malignant mesothelioma). It is dose-dependent, typically follows heavy cumulative exposure, and manifests after a long latency (commonly 20–40 years; ≥10 years minimum). (StatPearls, NBK555985; Merck Manual Professional)

Key identifiers. - MONDO: MONDO:0016466 - Disease Ontology: DOID:10320 - ICD-10-CM: J61 ("Pneumoconiosis due to asbestos and other mineral fibers") - ICD-11 (MMS): CA60.2 - MeSH: D001195 ("Asbestosis") - OMIM: Not applicable (not a Mendelian disorder) - Orphanet: Not a designated rare-disease entry (occupational/acquired; excluded from Orphanet's rare-disease scope)

Sources: Wikidata Q664174; MalaCards; ICD10Data J61

Common synonyms / alternative names. Pulmonary asbestosis; asbestos pneumoconiosis; interstitial pneumonitis due to asbestos; "white-lung" (colloquial). Note the important terminological distinction: asbestosis refers strictly to the parenchymal fibrosis, whereas "asbestos-related disease" is the broader umbrella.

Data derivation. Disease-level aggregated resources (occupational cohorts, national mortality/DALY databases, pathology case series, radiographic surveillance). There is no single OMIM/individual-patient genetic basis; population and cohort epidemiology dominate.

2. Etiology

Primary cause (environmental/occupational). Inhalation of respirable asbestos fibers with deposition in the distal airways and alveoli. Asbestos comprises two mineral families: - Serpentine — chrysotile ("white asbestos"): curly, flexible fibers; more readily cleared; historically the most-used commercial form. - Amphibole — crocidolite ("blue"), amosite ("brown"), tremolite, actinolite, anthophyllite: straight, stiff, needle-like, biopersistent, penetrate deeper and are more fibrogenic and carcinogenic. Amphiboles carry disproportionate pathogenic weight. (StatPearls, NBK555985)

Risk factors (environmental/occupational). - Cumulative exposure (dose) is the dominant determinant. A large Danish general-working-population cohort (1,514,136 workers; 1,084 incident asbestosis cases) found a fully adjusted incidence rate ratio of 1.18 per 1 f/ml-year (95% CI 1.15–1.22) and 1.94 for highest vs. lowest exposure tertile, with the steepest risk rise up to ~1 f/ml-year. "This study found exposure–response relations between cumulative asbestos exposure and incident asbestosis in the Danish general working population." (Iversen et al., Scand J Work Environ Health 2024; PMID: 38577971) - High-risk occupations: insulation/lagging, shipbuilding, asbestos mining/milling, textile manufacture, boiler work, brake/clutch manufacture, construction (asbestos-board installers and sprayers show the highest prevalence in some series — 38–39% in Japanese data), demolition, plumbing/pipefitting. (StatPearls) - Bystander and paraoccupational exposure (e.g., household members exposed to fibers on workers' clothing) and environmental/community exposure (near mines, from contaminated soils/building materials). - Fiber dimension & biopersistence: long, thin, durable amphibole fibers are most fibrogenic ("frustrated phagocytosis"). - Smoking: does not cause asbestosis per se but impairs mucociliary clearance, increases fiber retention, and interacts multiplicatively with asbestos for lung cancer risk (see §6, §11). - Male predominance and older age (reflecting historical occupational exposure patterns).

Genetic (susceptibility, not causal). Asbestosis has no single-gene cause. Candidate susceptibility/modifier loci — mostly studied for asbestos-related fibrotic and malignant endpoints — include: - GSTT1 null genotype: associated with fibrotic changes and reduced diffusing capacity; GSTM1 null: associated with thicker pleural plaques and increased risk across asbestos-linked diseases (plausibly via impaired conjugation/detoxification of ROS). (Franko et al., Eur Respir J 2011;38(3):672) - GSTM1 null + NAT2 slow acetylator each ~2-fold and together ~4-fold increased malignant mesothelioma risk in asbestos-exposed individuals. (Hirvonen et al., Cancer Res 1995;55:2981; PMID: 7606735) - Iron-homeostasis gene variants modulate mesothelioma susceptibility after exposure. (Frontiers Public Health 2023, PMC10628177)

Protective factors. No validated genetic protective allele for asbestosis. The only reliable protection is primary exposure prevention (fiber control, bans, PPE) and smoking avoidance/cessation (reduces synergistic cancer risk and slows functional decline). No dietary/antioxidant intervention has proven clinical benefit.

Gene–environment interaction. The paradigm is detoxification/oxidative-defense genotype × cumulative fiber burden: null GST genotypes and slow-acetylator NAT2 amplify oxidative and genotoxic injury from retained fibers, and smoking further raises fiber retention and cancer risk — a classic multiplicative environmental interaction. (CTD/PubMed as suggested sources.)

3. Phenotypes

Phenotype categories: symptoms, clinical signs, functional (PFT) abnormalities, radiographic/histopathologic findings, laboratory abnormalities. Onset is adult/late-adult after long latency; course is typically chronic and slowly progressive; frequencies below are approximate from clinical literature and should be curated with per-phenotype evidence.

Phenotype	Type	Suggested HPO term (verify)	Characteristics / frequency
Exertional dyspnea	Symptom	Exertional dyspnea HP:0002875	Earliest and most common; progressive; near-universal in symptomatic disease
Nonproductive (dry) cough	Symptom	Nonproductive cough HP:0031246	Common
Fatigue	Symptom	Fatigue HP:0012378	Common
Chest tightness/discomfort	Symptom	Chest pain HP:0100749	Occasional
Bibasilar fine end-inspiratory crackles ("velcro" rales)	Sign	Crackles HP:0030830	Characteristic; predominantly lower zones/posterolateral bases
Digital clubbing	Sign	Finger clubbing HP:0001217	~30–42% in some series; correlates with severity
Restrictive ventilatory defect (↓FVC, ↓TLC, preserved/↑FEV1/FVC)	PFT	Restrictive ventilatory defect HP:0002091	Hallmark functional pattern
Reduced diffusing capacity (↓DLCO)	PFT	Abnormal DLCO (verify HP)	Often earliest physiologic abnormality
Hypoxemia (rest or exertional)	Lab/functional	Hypoxemia HP:0012418	Advanced disease
Pulmonary fibrosis / reticular opacities	Imaging/path	Pulmonary fibrosis HP:0002206	Bilateral, lower-lobe/subpleural predominant
Honeycombing	Imaging/path	Honeycomb lung (verify HP)	End-stage
Pleural plaques / pleural thickening	Imaging/path	Pleural thickening HP:0002102 (verify)	Frequent concomitant marker of exposure
Cor pulmonale / right heart failure	Complication sign	Cor pulmonale HP:0001648 (verify)	Late/advanced
Respiratory failure	Complication	Respiratory insufficiency HP:0002093	End-stage

Severity & progression: ranges from mild/subclinical (radiographic only) to severe with respiratory failure. Progression is usually slow over years-to-decades, may continue after exposure ceases (retained biopersistent fibers), and is influenced by cumulative dose and continued smoking. Quality-of-life impact: dyspnea limits exertion and ADLs; advanced disease causes oxygen dependence, reduced exercise capacity, anxiety/depression, and (via lung-cancer/mesothelioma fear and surveillance) psychological burden. Pulmonary rehabilitation improves QoL and reduces hospitalization. (American Lung Association; PMID: 32053838)

4. Genetic / Molecular Information

Causal genes: None — asbestosis is caused by fiber exposure, not germline mutation.
Pathogenic variants: Not applicable in the ACMG/ClinVar sense. Relevant loci are susceptibility/modifier polymorphisms, not pathogenic variants: GSTM1 (HGNC:4632, null/deletion), GSTT1 (HGNC:4641, null/deletion), GSTP1 (HGNC:4638), GSTM3, EPHX1 (HGNC:3401), NAT2 (HGNC:7646, slow-acetylator haplotypes), SOD2/MnSOD. These are common-population polymorphisms (GSTM1/GSTT1 null genotypes are frequent, ~20–50% depending on ancestry), germline in origin, with functional consequences of reduced xenobiotic/ROS detoxification. (Eur Respir J 2011;38:672; Cancer Res 1995;55:2981)
Somatic vs germline: the above are germline modifiers; somatic genetic events (e.g., BAP1, NF2, CDKN2A losses) belong to the downstream malignancy (mesothelioma/lung cancer), not to asbestosis fibrosis itself.
Epigenetics: asbestos exposure induces DNA-methylation and miRNA changes in airway/lung tissue described chiefly in the carcinogenesis literature; a specific validated asbestosis (fibrosis) methylation signature is not established — mark as a knowledge gap.
Chromosomal abnormalities: none causal for asbestosis.

5. Environmental Information

Primary environmental agent: asbestos fibers (serpentine chrysotile; amphiboles crocidolite, amosite, tremolite, actinolite, anthophyllite). CHEBI/exposure suggestion: asbestos (verify CHEBI), silicon-containing mineral fiber; ROS species CHEBI:26523.
Co-exposures: other mineral dusts (silica → mixed-dust fibrosis), erionite (fibrous zeolite, mesothelioma), and cigarette smoke.
Lifestyle: cigarette smoking is the key modifiable co-factor — impairs mucociliary clearance (increasing fiber retention) and multiplies lung-cancer risk. No specific dietary driver established.
Infectious agents: None. Asbestosis is not infectious. (Secondary infections may complicate advanced disease.)

6. Mechanism / Pathophysiology

Overarching causal chain: inhaled biopersistent fiber deposition → alveolar macrophage "frustrated phagocytosis" → oxidative injury + inflammasome/cytokine activation → epithelial (type I/II pneumocyte) injury → fibroblast recruitment/activation → myofibroblast differentiation and excess ECM/collagen deposition → progressive interstitial fibrosis → impaired gas exchange and restrictive physiology → respiratory failure/cor pulmonale.

Step-by-step mechanism (upstream → downstream):

Fiber deposition & retention (trigger). Long, thin amphibole fibers deposit at alveolar-duct bifurcations; their length prevents complete macrophage engulfment ("frustrated phagocytosis"). Iron on/within fibers catalyzes redox chemistry. Cell types: alveolar macrophage (CL:0000583). GO: phagocytosis (GO:0006909).
Oxidative injury. Frustrated phagocytosis and fiber-surface iron generate ROS/RNS (Fenton-type chemistry, mitochondrial ROS), directly injuring type I pneumocytes (CL:0002062) and epithelium and activating redox-sensitive transcription factors (NF-κB). GO: reactive oxygen species metabolic process (GO:0072593); response to oxidative stress (GO:0006979).
Inflammasome activation & sterile inflammation. Asbestos activates the NLRP3 inflammasome in macrophages/monocytes and lung epithelial and mesothelial cells → caspase-1 → IL-1β (and IL-18) release; mitochondrial ROS and thioredoxin/TXNIP dissociation contribute. GO: inflammasome complex (GO:0061702); inflammatory response (GO:0006954). (Sayan & Mossman, Part Fibre Toxicol 2016;13:51, PMC5029018)
Fiber-size–dependent macrophage cell death (2023 mechanistic detail). "SFA [short-fiber amosite] internalization resulted in pyroptotic-related immunogenic cell death (ICD) characterized by the release of the pro-inflammatory damage signal (DAMP) IL-1α after inflammasome activation and gasdermin D (GSDMD)-pore formation." By contrast, "macrophage responses to non-internalizable LFA [long-fiber amosite] were associated with tumor necrosis factor alpha (TNF-α) release, caspase-3 and -7 activation, and apoptosis." Short fibers signalled via TLR4; long fibers via MARCO/SR-A6 + ROS cascade + TLR4. GO: pyroptosis (GO:0070269); apoptotic process (GO:0006915). (Della Latta-type study; PMID: 37894824, 2023)
Pro-fibrotic mediator surge. Activated macrophages release TNF-α, IL-1β, PDGF, TGF-β, IGF-1, fibronectin. IL-1β/NLRP3 signalling promotes TGF-β pathways. Macrophages transition from a pro-inflammatory (M1) to a wound-healing (M2) phenotype driving repair-gone-awry. GO: transforming growth factor beta receptor signaling pathway (GO:0007179); cytokine-mediated signaling (GO:0019221).
Fibroblast activation & myofibroblast transdifferentiation. TGF-β drives fibroblast proliferation and fibroblast→myofibroblast differentiation (α-SMA+), plus epithelial–mesenchymal transition contributions. Cells: fibroblast (CL:0000057), myofibroblast (CL:0000186). GO: fibroblast proliferation (GO:0048144); epithelial to mesenchymal transition (GO:0001837).
Excess ECM/collagen deposition. Myofibroblasts deposit type I/III collagen and matrix → interstitial thickening. GO: collagen fibril organization (GO:0030199); extracellular matrix organization (GO:0030198). This is the principal pathogenic endpoint ("interstitial fibrosis is regarded as the principal pathogenic mechanism of asbestosis").
Structural/functional consequence. Alveolar-wall thickening and honeycombing impair diffusion and compliance → restrictive physiology, ↓DLCO, hypoxemia → pulmonary hypertension → cor pulmonale.

Immune involvement: sterile, chronic innate-immune-driven inflammation (macrophage/inflammasome-centric) rather than autoimmunity — though autoantibodies (ANA, RF) may be elevated. Tissue-damage mechanisms: oxidative stress, sterile inflammation, and fibrosis. Biochemical/protein dysfunction: no enzyme defect; the "dysfunction" is dysregulated cytokine/TGF-β signalling and matrix homeostasis. Molecular profiling: transcriptomic/innate-immunity gene-expression signatures associated with asbestos fibrotic change are reported (PMC3888604); dedicated proteomic/metabolomic/single-cell asbestosis signatures are limited — knowledge gap.

Histopathology (CAP/Pulmonary Pathology Society criteria): diffuse interstitial fibrosis in the proper anatomic distribution plus identifiable asbestos (ferruginous) bodies (golden-brown, beaded/dumbbell iron-protein-coated fibers) or documented elevated fiber burden. Fibrosis is graded, subpleural/lower-lobe predominant. (Roggli et al., Arch Pathol Lab Med 2010;134:462; ATS mechanisms review, AJRCCM 1998;157:1666)

7. Anatomical Structures Affected

Primary organ: lung (UBERON:0002048) — bilateral, lower-lobe (UBERON:0008953) and subpleural/peripheral predominance; alveolus of lung (UBERON:0002299) and pulmonary interstitium.
Secondary/associated: pleura (UBERON:0000977) — visceral pleural thickening, plaques; heart (right ventricle → cor pulmonale); systemic effects of chronic hypoxemia.
Body systems: respiratory (primary); cardiovascular (secondary, pulmonary hypertension/right heart).
Tissue level: alveolar epithelium (type I/II pneumocytes), pulmonary interstitial connective tissue, pleural mesothelium.
Cell populations: alveolar macrophage (CL:0000583), pulmonary alveolar type 1 cell (CL:0002062), type 2 pneumocyte (CL:0002063), fibroblast (CL:0000057) / myofibroblast (CL:0000186), mesothelial cell (CL:0000077).
Subcellular: mitochondria (mito-ROS; GO:0005739), lysosome/phagosome (frustrated phagocytosis; GO:0005764), extracellular region/matrix (GO:0031012).
Localization/lateralization: bilateral, lower-zone and posterolateral/subpleural predominant.

8. Temporal Development

Onset: adult/late-adult, after prolonged latency of ~20–40 years from first exposure (minimum ~10 years; shorter with very intense exposure). Onset is insidious/chronic.
Progression/stages: subclinical/radiographic → mild symptomatic (exertional dyspnea, ↓DLCO) → moderate (restrictive PFT, hypoxemia) → advanced/end-stage (honeycombing, respiratory failure, cor pulmonale). Rate is usually slow and variable over years.
Course: chronic, irreversible and often progressive even after exposure ceases (biopersistent retained fibers); no spontaneous remission. There is no treatment-induced remission; management slows decline and treats complications.
Critical window: the actionable window is exposure prevention before disease onset; once fibrosis is established it is not reversible.

9. Inheritance and Population

Inheritance: Not applicable — acquired occupational/environmental disease; genetic contribution is modifier/susceptibility polygenic (GST/NAT2/iron-homeostasis alleles), not Mendelian. No penetrance, anticipation, mosaicism, or carrier-frequency concepts apply.
Epidemiology (global burden): In 2019, occupational asbestos exposure was linked to ~239,330 deaths and ~4,189,000 DALYs globally; global asbestos-attributed deaths rose ~65.7% (1990–2019). WHO-type estimates attribute ~55,000+ deaths/year to asbestos-related disease broadly. In the US, absolute deaths rose but age-standardized mortality and DALY rates declined over 1990–2019 (reflecting historical-exposure cohort aging plus reduced new exposure). (Merck Manual; StatPearls)
Incidence in exposed cohorts: ~0.71 asbestosis cases per 100,000 person-years baseline in a general-working-population cohort, rising steeply with cumulative exposure (IRR 1.18 per f/ml-year). (PMID: 38577971)
Demographics: male predominance (occupational exposure history), older age at diagnosis. Geographic variation tracks historical mining/industrial use and regulatory timelines — declining in countries with asbestos bans, still rising in regions with ongoing chrysotile use. Prevalence extremely high in specific trades (e.g., asbestos-board installers ~39% in Japanese series). Prevalence class: occupational-cohort-dependent; in the general population it is uncommon.

10. Diagnostics

Diagnosis rests on the triad of (1) credible exposure history with appropriate latency, (2) imaging/pathologic evidence of diffuse interstitial fibrosis, and (3) exclusion of alternatives.

Exposure history: occupational/paraoccupational/environmental asbestos exposure, typically ≥10–20 years prior.
Imaging:
Chest radiograph: bilateral lower-zone reticular/linear opacities (ILO-classified small irregular opacities), ± pleural plaques/thickening; "shaggy heart border."
HRCT (most sensitive): subpleural/basal reticulation, interlobular/intralobular septal thickening, subpleural curvilinear/branching lines, parenchymal bands, ground-glass, honeycombing; pleural plaques strongly support asbestos etiology and help distinguish from IPF.
Pulmonary function tests: restrictive pattern (↓FVC, ↓TLC, normal/↑FEV1/FVC), reduced DLCO (often earliest), exertional desaturation on 6-minute walk. (LOINC-coded spirometry/DLCO.)
Histopathology (when biopsy done): diffuse interstitial fibrosis plus asbestos/ferruginous bodies or elevated tissue fiber burden (CAP/PPS criteria); asbestos-body quantification and fiber analysis (SEM/EDX) on digested tissue in reference labs.
Laboratory: no specific diagnostic biomarker; nonspecific ↑CRP/ESR, and sometimes ↑RF/ANA. Serum mesothelin/osteopontin relate to mesothelioma, not asbestosis diagnosis.
Clinical criteria / differential: Differentiate from idiopathic pulmonary fibrosis (UIP) — asbestosis favored by exposure history + pleural plaques + asbestos bodies; also from other pneumoconioses, hypersensitivity pneumonitis, connective-tissue-disease ILD, sarcoidosis, drug-induced fibrosis. A 2024 clinicopathological series of 102 cases refined 21st-century diagnostic correlation. (PMID: 38192052; Merck Manual)
Genetic/omics testing: Not used diagnostically. Newborn/carrier/cascade screening: not applicable.
Screening: medical surveillance of exposed workers (periodic spirometry + low-dose CT), and lung-cancer LDCT screening consideration in exposed (especially smoking) individuals.

11. Outcome / Prognosis

Course/survival: highly variable. Many patients have mild, slowly progressive disease and near-normal life expectancy; a subset progress to respiratory failure and cor pulmonale. Some clinical sources cite limited survival once symptomatic and worse outcomes with pleural involvement, but survival is heterogeneous and dose/severity-dependent. Progression can continue after exposure ends. (StatPearls; Merck Manual)
Morbidity/disability: progressive exertional limitation, oxygen dependence, reduced QoL.
Complications:
Bronchogenic lung cancer — the most common asbestos-related malignancy; risk multiplies synergistically with smoking (asbestos + smoking risk far exceeds additive).
Malignant pleural/peritoneal mesothelioma — >80% attributable to asbestos; long latency (30–40+ yr); not smoking-related.
Cor pulmonale / right heart failure, respiratory failure, recurrent respiratory infection, pulmonary hypertension.
Associations with laryngeal and ovarian cancer (IARC).
Prognostic factors: cumulative exposure/fiber burden, extent/rate of radiographic progression, baseline and decline in FVC/DLCO, degree of hypoxemia, continued smoking, age/comorbidity.

12. Treatment

No curative or disease-reversing therapy exists; management is supportive, prevents progression, and treats complications. (Suggested MAXO terms in brackets — verify with OAK.)

Exposure cessation — remove from further asbestos and irritant exposure (foundational).
Smoking cessation — highest-yield intervention to reduce lung-cancer risk and slow decline. [smoking cessation — MAXO, verify]
Supplemental long-term oxygen therapy for resting/exertional hypoxemia (PaO₂ < ~55 mmHg). [oxygen administration — MAXO, verify]
Pulmonary rehabilitation (exercise + breathing training + education) — improves QoL, exertional capacity, reduces hospitalization. [physical therapy MAXO:0000011 / pulmonary rehabilitation — verify] (ALA; PMID: 32053838)
Vaccination — influenza and pneumococcal to prevent respiratory infection. [vaccination MAXO:0001017 — verify]
Management of cor pulmonale / heart failure and pulmonary hypertension — supportive/pharmacologic. [supportive care MAXO:0000950 — verify]
Corticosteroids — sometimes used for inflammation, but evidence of benefit in established asbestosis is weak (not standard disease-modifying therapy). [pharmacotherapy — glucocorticoid, verify CHEBI prednisolone CHEBI:8378]
Lung transplantation — for selected end-stage patients (double-lung preferred). [organ transplantation MAXO:0010039 / lung transplantation — verify]
Malignancy surveillance/treatment — LDCT lung-cancer screening in appropriate exposed/smoking patients; oncologic management of lung cancer/mesothelioma as indicated.
Antifibrotics (pirfenidone, nintedanib): approved for IPF and progressive pulmonary fibrosis phenotypes; experimental/off-label in asbestosis with progressive fibrosing behavior — an active area but not established standard of care (basis for clinical-trial follow-up). (asbestos.com treatment overview; StatPearls)
Pharmacogenomics: none specific/validated for asbestosis.

13. Prevention

Primary prevention (most important): eliminate/control exposure — national asbestos bans, permissible-exposure-limit enforcement (OSHA), engineering controls (wet methods, enclosure, ventilation), respiratory PPE, safe removal/abatement, and product substitution. Historical latency means primary prevention today prevents disease decades hence.
Secondary prevention: medical surveillance of exposed workers (periodic spirometry/DLCO, chest imaging), early identification, and smoking-cessation programs in exposed populations; LDCT lung-cancer screening in high-risk exposed smokers.
Tertiary prevention: vaccinations, pulmonary rehab, prompt infection treatment, oxygen, comorbidity and malignancy management to limit complications.
Public-health/environmental: worldwide asbestos-use bans (advocated by WHO), safe demolition/renovation regulation, environmental remediation of contaminated sites.
Genetic counseling / immunization against causal agent: not applicable (no vaccine; not heritable).

Sources: CDC/ATSDR asbestos toxicity module; ALA.

14. Other Species / Natural Disease

Taxonomy: primarily Homo sapiens (NCBITaxon:9606). Asbestosis is fundamentally a human occupational disease.
Naturally occurring animal disease: rare/limited. Experimental asbestos-induced pulmonary fibrosis is well documented in laboratory rodents; naturally occurring companion-animal asbestosis is not a recognized clinical entity, though environmental asbestos exposure has been studied in pets as a sentinel for human household exposure (mesothelioma associations in dogs).
Comparative biology: the macrophage-frustrated-phagocytosis/ROS/fibrosis mechanism is evolutionarily conserved across mammals, which underpins rodent modeling.
Zoonotic potential: none (non-infectious).

15. Model Organisms

Rodent inhalation/instillation models (mammalian): rat and mouse intratracheal instillation or inhalation of chrysotile/crocidolite/amosite reproduce alveolar macrophage accumulation, inflammation, and peribronchiolar/interstitial fibrosis — the workhorse asbestosis models. [MGI/RGD]
In vitro / cellular: murine and human alveolar macrophage cultures (frustrated phagocytosis, NLRP3/IL-1β, ROS; short vs long amosite fiber studies, PMID: 37894824); mesothelial cell and lung epithelial cultures for inflammasome and TGF-β/fibroblast-activation assays; fibroblast/myofibroblast differentiation assays.
Genetic models: Nlrp3-, Casp1-, Tnf-, Il1r-, and Tgfb-pathway knockout/transgenic mice used to dissect individual mechanistic steps (inflammasome, TNF, TGF-β signalling).
Phenotype recapitulation: rodent models reproduce the inflammation→fibrosis cascade and fiber-size/biopersistence effects well.
Limitations: accelerated timelines (weeks–months vs. human decades of latency), high bolus doses unlike chronic low-level human exposure, species differences in fiber clearance and airway anatomy, and incomplete modeling of honeycomb end-stage architecture and of asbestos-associated human malignancy latency.
Resources: MGI, RGD, Alliance of Genome Resources, IMPC (for pathway-gene knockouts); Cellosaurus/ATCC for macrophage and mesothelial cell lines.

Consolidated Ontology Term Suggestions (verify all with OAK/OLS before curation)

MONDO: MONDO:0016466 (asbestosis)
HP (phenotypes): HP:0002875 exertional dyspnea; HP:0031246 nonproductive cough; HP:0030830 crackles; HP:0001217 finger clubbing; HP:0002091 restrictive ventilatory defect; HP:0012418 hypoxemia; HP:0002206 pulmonary fibrosis; HP:0002102 pleural thickening (verify); HP:0001648 cor pulmonale (verify); HP:0002093 respiratory insufficiency; HP:0012378 fatigue
GO (processes): GO:0006909 phagocytosis; GO:0072593 ROS metabolic process; GO:0006954 inflammatory response; GO:0061702 inflammasome complex; GO:0070269 pyroptosis; GO:0006915 apoptotic process; GO:0007179 TGF-β receptor signaling; GO:0048144 fibroblast proliferation; GO:0001837 EMT; GO:0030199 collagen fibril organization; GO:0030198 ECM organization
CL (cell types): CL:0000583 alveolar macrophage; CL:0002062 type 1 pneumocyte; CL:0002063 type 2 pneumocyte; CL:0000057 fibroblast; CL:0000186 myofibroblast; CL:0000077 mesothelial cell
UBERON (anatomy): UBERON:0002048 lung; UBERON:0008953 lower lobe of lung; UBERON:0002299 alveolus of lung; UBERON:0000977 pleura
CHEBI: CHEBI:26523 reactive oxygen species; asbestos/mineral-fiber term (verify); CHEBI:8378 prednisolone; CHEBI:15379 dioxygen (O₂)
MAXO (treatments): oxygen administration (verify); MAXO:0000011 physical therapy (pulmonary rehab); MAXO:0001017 vaccination; MAXO:0010039 organ transplantation (lung transplant); MAXO:0000950 supportive care
HGNC (modifier genes): HGNC:4632 GSTM1; HGNC:4641 GSTT1; HGNC:4638 GSTP1; HGNC:3401 EPHX1; HGNC:7646 NAT2

Key Citations (for evidence items)

Claim	Source	PMID / DOI
Exposure–response, IRR 1.18 per f/ml-year, Danish cohort	Iversen et al., Scand J Work Environ Health 2024	PMID: 38577971 (PMC11245331)
Short- vs long-fiber amosite macrophage mechanisms (pyroptosis/IL-1α/GSDMD vs TNF-α/caspase-3,7/apoptosis)	2023 macrophage study	PMID: 37894824 (PMC10606797)
NLRP3 inflammasome in particle/fiber lung disease	Sayan & Mossman, Part Fibre Toxicol 2016;13:51	doi:10.1186/s12989-016-0162-4 (PMC5029018)
Diagnostic clinicopathological correlation, 102 cases (21st c.)	2024 series	PMID: 38192052 (PubMed)
GSTM1/GSTT1 susceptibility to asbestos fibrotic change	Franko et al., Eur Respir J 2011;38:672	ERJ
GSTM1 null + NAT2 slow acetylator ~4× mesothelioma risk	Hirvonen et al., Cancer Res 1995;55:2981	PMID: 7606735
Pathology diagnostic criteria (CAP/PPS)	Roggli et al., Arch Pathol Lab Med 2010;134:462	Article
Mechanisms of asbestosis & silicosis	Mossman & Churg, AJRCCM 1998;157:1666	ATS
Non-linear dose-response for respirable mineral fibers	2018 review	PMID: 29932955 (PubMed)
Clinical overview, latency, PFT, treatment, prognosis	StatPearls / Merck Manual	NBK555985; Merck

Evidence-source classification reminder for curation: the fiber/macrophage mechanism papers (PMID 37894824; PFT 2016 review) are IN_VITRO; the Danish cohort (PMID 38577971) and clinicopathological series (PMID 38192052) are HUMAN_CLINICAL; rodent inhalation studies are MODEL_ORGANISM. Per the dismech DR/anti-hallucination SOP, each PMID must be re-fetched with just fetch-reference and each snippet verified as an exact substring, and every ontology ID validated with OAK, before committing to a KB entry.

Explicitly not available / not applicable for asbestosis: OMIM entry, Mendelian causal gene, inheritance pattern, penetrance/anticipation/carrier frequency, newborn/carrier screening, gene therapy, and a validated diagnostic molecular biomarker — all reflect that this is an acquired occupational fibrotic disease rather than a genetic disorder.

Ask OpenScientist

OpenScientist Report

Classifications

Discussions and Knowledge Gaps

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Diagnosis

Progression

Prevalence

Clinical Burden

Differential Diagnoses

Related Datasets

Clinical Trials

Experimental Models

Animal Models

Source YAML

References & Deep Research

Deep Research

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic / Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome / Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Consolidated Ontology Term Suggestions (verify all with OAK/OLS before curation)

Key Citations (for evidence items)